<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria - Zani, B - 2014 | Cochrane Library</title> <meta content="Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria - Zani, B - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010927/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria - Zani, B - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010927/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010927" name="dc.identifier" scheme="DOI"/> <meta content="Dihydroartemisinin‐piperaquine for treating uncomplicated &lt;i&gt;Plasmodium falciparum&lt;/i&gt; malaria" name="citation_title"/> <meta content="Babalwa Zani" name="citation_author"/> <meta content="South African Medical Research Council" name="citation_author_institution"/> <meta content="Michael Gathu" name="citation_author"/> <meta content="KEMRI‐Wellcome Trust Research Programme" name="citation_author_institution"/> <meta content="Sarah Donegan" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Piero L Olliaro" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="David Sinclair" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="sinclad@liverpool.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010927" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010927/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010927/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010927/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimalarials [*therapeutic use]; Artemether, Lumefantrine Drug Combination; Artemisinins [*therapeutic use]; Artesunate; Drug Combinations; Drug Therapy, Combination [methods]; Ethanolamines [therapeutic use]; Fluorenes [therapeutic use]; Malaria, Falciparum [*drug therapy]; Mefloquine [therapeutic use]; Parasitemia [drug therapy]; Quinolines [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010927&amp;doi=10.1002/14651858.CD010927&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010927\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010927\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD010927",title:"Dihydroartemisinin\\u2010piperaquine for treating uncomplicated   \u003ci\u003ePlasmodium falciparum\u003c/i\u003e malaria",firstPublishedDate:"Jan 20, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010927&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010927';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010927/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010927/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010927%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010927/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010927/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010927/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010927/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010927" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010927/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010927" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010927/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010927/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4354 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010927" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010927/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/appendices#CD010927-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/table_n/CD010927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/table_n/CD010927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010927/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010927/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010927/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010927/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD010927/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Dihydroartemisinin‐piperaquine for treating uncomplicated <i>Plasmodium falciparum</i> malaria </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010927/information#CD010927-cr-0002">Babalwa Zani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010927/information#CD010927-cr-0003">Michael Gathu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010927/information#CD010927-cr-0004">Sarah Donegan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010927/information#CD010927-cr-0005">Piero L Olliaro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010927/information#CD010927-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>David Sinclair</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010927/information/en#CD010927-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010927/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010927">https://doi.org/10.1002/14651858.CD010927</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010927-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010927-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010927-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010927-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010927-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010927-abs-0001" lang="en"> <section id="CD010927-sec-0001"> <h3 class="title" id="CD010927-sec-0001">Background</h3> <p>The World Health Organization (WHO) recommends Artemisinin‐based Combination Therapy (ACT) for treating uncomplicated <i>Plasmodium falciparum</i> malaria. This review aims to assist the decision‐making of malaria control programmes by providing an overview of the relative effects of dihydroartemisinin‐piperaquine (DHA‐P) versus other recommended ACTs. </p> </section> <section id="CD010927-sec-0002"> <h3 class="title" id="CD010927-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of DHA‐P compared to other ACTs for treating uncomplicated <i>P. falciparum</i> malaria in adults and children. </p> </section> <section id="CD010927-sec-0003"> <h3 class="title" id="CD010927-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL) published in <i>The Cochrane Library</i>; MEDLINE; EMBASE; LILACS, and the metaRegister of Controlled Trials (mRCT) up to July 2013. </p> </section> <section id="CD010927-sec-0004"> <h3 class="title" id="CD010927-sec-0004">Selection criteria</h3> <p>Randomized controlled trials comparing a three‐day course of DHA‐P to a three‐day course of an alternative WHO recommended ACT in uncomplicated <i>P. falciparum</i> malaria. </p> </section> <section id="CD010927-sec-0005"> <h3 class="title" id="CD010927-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in line with the WHO 'Protocol for assessing and monitoring antimalarial drug efficacy’ and compared drugs using risk ratios (RR) and 95% confidence intervals (CI). Secondary outcomes were effects on gametocytes, haemoglobin, and adverse events. We assessed the quality of evidence using the GRADE approach. </p> </section> <section id="CD010927-sec-0006"> <h3 class="title" id="CD010927-sec-0006">Main results</h3> <p>We included 27 trials, enrolling 16,382 adults and children, and conducted between 2002 and 2010. Most trials excluded infants aged less than six months and pregnant women. </p> <p><i>DHA‐P versus artemether‐lumefantrine</i> </p> <p>In Africa, over 28 days follow‐up, DHA‐P is superior to artemether‐lumefantrine at preventing further parasitaemia (PCR‐unadjusted treatment failure: RR 0.34, 95% CI 0.30 to 0.39, nine trials, 6200 participants, <i>high quality evidence</i> ), and although PCR‐adjusted treatment failure was below 5% for both ACTs, it was consistently lower with DHA‐P (PCR‐adjusted treatment failure: RR 0.42, 95% CI 0.29 to 0.62, nine trials, 5417 participants, <i>high quality evidence</i> ). DHA‐P has a longer prophylactic effect on new infections which may last for up to 63 days (PCR‐unadjusted treatment failure: RR 0.71, 95% CI 0.65 to 0.78, two trials, 3200 participants, <i>high quality evidence</i>). </p> <p>In Asia and Oceania, no differences have been shown at day 28 (four trials, 1143 participants, <i>moderate quality evidence</i> ), or day 63 (one trial, 323 participants, <i>low quality evidence</i>). </p> <p>Compared to artemether‐lumefantrine, no difference was seen in prolonged QTc (<i>low quality evidence</i> ), and no cardiac arrhythmias were reported. The frequency of other adverse events is probably similar with both combinations (<i>moderate quality evidence</i>). </p> <p><i>DHA‐P versus artesunate plus mefloquine</i> </p> <p>In Asia, over 28 days follow‐up, DHA‐P is as effective as artesunate plus mefloquine at preventing further parasitaemia (PCR‐unadjusted treatment failure: eight trials, 3487 participants, <i>high quality evidence</i> ). Once adjusted by PCR to exclude new infections, treatment failure at day 28 was below 5% for both ACTs in all eight trials, but lower with DHA‐P in two trials (PCR‐adjusted treatment failure: RR 0.41 95% CI 0.21 to 0.80, eight trials, 3482 participants, <i>high quality evidence</i> ). Both combinations contain partner drugs with very long half‐lives and no consistent benefit in preventing new infections has been seen over 63 days follow‐up (PCR‐unadjusted treatment failure: five trials, 2715 participants, <i>moderate quality evidence</i>). </p> <p>In the only trial from South America, there were fewer recurrent parastaemias over 63 days with artesunate plus mefloquine (PCR‐unadjusted treatment failure: RR 6.19, 95% CI 1.40 to 27.35, one trial, 445 participants, <i>low quality evidence</i> ), but no differences were seen once adjusted for new infections (PCR‐adjusted treatment failure: one trial, 435 participants, <i>low quality evidence</i>). </p> <p>DHA‐P is associated with less nausea, vomiting, dizziness, sleeplessness, and palpitations compared to artesunate plus mefloquine (<i>moderate quality evidence</i> ). DHA‐P was associated with more frequent prolongation of the QTc interval (<i>low quality evidence</i>), but no cardiac arrhythmias were reported. </p> </section> <section id="CD010927-sec-0007"> <h3 class="title" id="CD010927-sec-0007">Authors' conclusions</h3> <p>In Africa, dihydroartemisinin‐piperaquine reduces overall treatment failure compared to artemether‐lumefantrine, although both drugs have PCR‐adjusted failure rates of less than 5%. In Asia, dihydroartemisinin‐piperaquine is as effective as artesunate plus mefloquine, and is better tolerated. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010927-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010927-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010927-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010927-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010927-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010927-abs-0004" lang="en"> <h3>Dihydroartemisinin‐piperaquine for treating uncomplicated malaria</h3> <p>This review summarises trials evaluating the effects of dihydroartemisinin‐piperaquine (DHA‐P) compared to other artemisinin‐based combination therapies recommended by the World Health Organization. After searching for relevant trials up to July 2013, we included 27 randomized controlled trials, enrolling 16,382 adults and children and conducted between 2002 and 2010. </p> <p><i><b>What is uncomplicated malaria and how might dihydroartemisinin‐piperaquine work</b> </i> </p> <p>Uncomplicated malaria is the mild form of malaria which usually causes a fever, with or without headache, tiredness, muscle pains, abdominal pains, nausea, and vomiting. If left untreated, uncomplicated malaria can develop into severe malaria with kidney failure, breathing difficulties, fitting, unconsciousness, and eventually death. </p> <p>DHA‐P is one of five artemisinin‐based combination therapies the World Health Organization currently recommends to treat malaria. These combinations contain an artemisinin component (such as dihydroartemisinin) which works very quickly to clear the malaria parasite from the person's blood, and a longer acting drug (such as piperaquine) which clears the remaining parasites from the blood and may prevent new infections with malaria for several weeks. </p> <p><i><b>What the research says</b> </i> </p> <p><i>DHA‐P versus artemether lumefantrine</i> </p> <p>In studies of people living in Africa, both DHA‐P and artemether‐lumefantrine are very effective at treating malaria (<i>high quality evidence</i> ). However, DHA‐P cures slightly more patients than artemether‐lumefantrine, and it also prevents further malaria infections for longer after treatment (<i>high quality evidence</i> ). DHA‐P and artemether‐lumefantrine probably have similar side effects (<i>moderate quality evidence</i>). </p> <p><i>DHA‐P versus artesunate plus mefloquine</i> </p> <p>In studies of people living in Asia, DHA‐P is as effective as artesunate plus mefloquine at treating malaria (<i>moderate quality evidence</i> ). Artesunate plus mefloquine probably causes more nausea, vomiting, dizziness, sleeplessness, and palpitations than DHA‐P (<i>moderate quality evidence</i>). </p> <p>Overall, in some people, DHA‐P has been seen to cause short term changes in electrocardiographs tracing the conduction of the heart rhythm (<i>low quality evidence</i>), but these small changes on the electrocardiograph resolved within one week without serious consequences. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010927-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010927-sec-0099"></div> <h3 class="title" id="CD010927-sec-0100">Implications for practice</h3> <section id="CD010927-sec-0100"> <p>In Africa, DHA‐P seems to reduce treatment failure compared to AL6, although it should be noted that AL6 also performed above the WHO standard of 95% cure rate in all these trials. DHA‐P therefore represents an effective alternative with a simplified dosing regimen, and a longer post‐treatment prophylactic effect. </p> <p>In Asia, DHA‐P appears to be as effective as the widely used AS+MQ, and is better tolerated. This may promote DHA‐P to become the first line treatment option. </p> </section> <h3 class="title" id="CD010927-sec-0101">Implications for research</h3> <section id="CD010927-sec-0101"> <p>The efficacy of DHA‐P is now well established. Future research should concentrate on safety surveillance, particularly in infants and pregnant women, and further appraisal of the potential effects on cardiac conduction. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010927-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010927-sec-0023"></div> <div class="table" id="CD010927-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Africa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated <i>P. falciparum</i> malaria in Africa</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Malaria endemic settings in Africa<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artemether‐lumefantrine (AL6) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> AL6</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.34</b> <br/> (0.30 to 0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6200<br/> (9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (7 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.42</b> <br/> (0.29 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5417<br/> (9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.71</b> <br/> (0.65 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3200<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,3,4,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (29 to 35) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.72</b> <br/> (0.50 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2097<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,3,7,8,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.,<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of studies at high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in different transmission settings in East, West and Southern Africa. Most studies were limited to children.<br/> <sup>4</sup> No serious imprecision: Both limits of the 95% CI imply appreciable benefit, and the overall meta‐analysis is adequately powered to detect this result.<br/> <sup>5</sup> No serious imprecision: Although there is a benefit in favour of DHA‐P, PCR‐adjusted treatment failure was below 5% with both drugs.<br/> <sup>6</sup> No serious inconsistency: At this timepoint there is more inconsistency between trials. Both show a benefit with DHA‐P but there is variation in the size of this benefit.<br/> <sup>7</sup> Seven studies from East, West and Southern Africa reported outcomes at day 42. At this timepoint DHA‐P still had an advantage over AL6 on PCR‐unadjusted treatment failure (RR 0.60, 95% CI 0.53 to 0.67, seven studies, 3301, <i>high quality evidence</i> ), and PCR‐adjusted treatment failure (RR 0.58, 95% CI 0.41 to 0.81, seven studies, 2559 participants, <i>moderate quality evidence</i>).<br/> <sup>8</sup> No serious inconsistency: Statistical heterogeneity was low.<br/> <sup>9</sup> No serious imprecision: Both ACTs performed well in these two trials with low levels of treatment failure. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010927-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010927-sec-0024"></div> <section id="CD010927-sec-0025"> <h3 class="title" id="CD010927-sec-0025">Description of the condition</h3> <p>Malaria is a febrile illness caused by infection with the protozoan parasite <i>Plasmodium</i> , which is transmitted from person to person by the bite of infected female <i>Anopheles</i> mosquitoes. Five <i>Plasmodium</i> species are capable of causing malaria in humans, of which <i>P. falciparum</i> is responsible for over 90% of malaria cases and almost all of the malaria deaths worldwide (<a href="./references#CD010927-bbs2-0072" title="WHO Global Malaria Programme. World Malaria Report 2012. World Malaria Report 2012. Geneva: World Health Organization, 2012. ">WHO 2012</a>). </p> <p>Uncomplicated malaria is the mild form of the disease which typically presents as a fever, with or without associated headache, tiredness, muscle pains, abdominal pains, rigors (severe shivering), nausea, and vomiting. If left untreated <i>P. falciparum</i> malaria can rapidly develop into severe malaria with consequent renal failure (kidney failure), pulmonary oedema (fluid in the lungs), convulsions (fitting), coma, and eventually death (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>; <a href="./references#CD010927-bbs2-0066" title="SinclairD , DoneganS , IsbaR , LallooDG . Artesunate versus quinine for treating severe malaria. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005967.pub4] ">Sinclair 2012</a>). A clinical diagnosis of malaria can be confirmed by detection of the malaria parasite in the patient's blood. This has traditionally been done by light microscopy but increasingly rapid diagnostic tests are being used (<a href="./references#CD010927-bbs2-0044" title="AbbaK , DeeksJJ , OlliaroP , NaingCM , JacksonSM , TakwoingiY , et al. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD008122.pub2] ">Abba 2011</a>). </p> <p>Resistance of <i>P. falciparum</i> to the traditional antimalarial drugs (such as chloroquine, sulfadoxine‐pyrimethamine, amodiaquine, and mefloquine) is a growing problem and is thought to have contributed to increased malaria mortality in recent years (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). Chloroquine resistance has now been documented in all regions except Central America and the Caribbean. There is high‐level resistance to sulfadoxine‐pyrimethamine throughout South East Asia and increasingly in Africa, and mefloquine resistance is common in the border areas of Cambodia, Myanmar, and Thailand (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>; <a href="./references#CD010927-bbs2-0073" title="WorldWide Antimalarial Resistance Network (WWARN). WWARN. http://www.wwarn.org/about‐us/our‐work2013. ">WWARN 2013</a>). </p> <p>To combat the spread of resistance, the World Health Organization (WHO) now recommends that <i>P. falciparum</i> malaria is always treated using a combination of two drugs that act at different biochemical sites within the parasite (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). If a parasite mutation producing drug resistance arises spontaneously during treatment, the parasite should then be killed by the partner drug, thus reducing or delaying the development of resistance and increasing the useful lifetime of the individual drugs (<a href="./references#CD010927-bbs2-0068" title="WhiteNJ , OlliaroPL . Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitology Today1996;12(10):399‐401. ">White 1996</a>; <a href="./references#CD010927-bbs2-0069" title="WhiteNJ , NostenF , LooareesuwanS , WatkinsWM , MarshK , SnowRW , et al. Averting a malaria disaster. The Lancet1999;353(9168):1965‐7. ">White 1999</a>). The current drug combinations all include a short‐acting artemisinin derivative (such as artesunate, artemether, or dihydroartemisinin), partnered with a longer‐acting drug in combinations known as 'Artemisinin‐based Combination Therapies' (ACTs). </p> </section> <section id="CD010927-sec-0026"> <h3 class="title" id="CD010927-sec-0026">Description of the intervention</h3> <p>The WHO recommends five ACTs for treating uncomplicated <i>P. falciparum</i> malaria: dihydroartemisinin‐piperaquine (DHA‐P); artesunate plus mefloquine (AS+MQ); artemether‐lumefantrine ‐ six doses regimen (AL6); artesunate plus amodiaquine (AS+AQ); and artesunate plus sulfadoxine‐pyrimethamine (AS+SP) (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). </p> <p>Dihydroartemisinin is the active metabolite of the artemisinin derivatives, and produces faster relief of clinical symptoms and faster clearance of parasites from the blood than other antimalarial drugs (<a href="./references#CD010927-bbs2-0056" title="McIntoshHM , OlliaroP . Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000256] ">McIntosh 2000</a>; <a href="./references#CD010927-bbs2-0045" title="AdjuikM , BabikerA , GarnerP , OlliaroP , TaylorW , WhiteN , et al. Artesunate combinations for treatment of malaria: meta‐analysis. The Lancet2004;363(9402):9‐17. ">Adjuik 2004</a>; <a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). When used as a monotherapy, the short half‐life of the artemisinin derivatives (and rapid elimination from the blood) means that patients must take the drug for at least seven days (<a href="./references#CD010927-bbs2-0057" title="MeshnickSR , TaylorTE , KamchonwongpaisanS . Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiological Reviews1996;60(2):301‐15. ">Meshnick 1996</a>; <a href="./references#CD010927-bbs2-0045" title="AdjuikM , BabikerA , GarnerP , OlliaroP , TaylorW , WhiteN , et al. Artesunate combinations for treatment of malaria: meta‐analysis. The Lancet2004;363(9402):9‐17. ">Adjuik 2004</a>). Failure to complete the course, due to the rapid improvement in clinical symptoms, can lead to high levels of treatment failure even in the absence of drug resistance. The long‐acting partner drug in ACTs therefore allows the artemisinin component to be taken for a shorter duration (<a href="./references#CD010927-bbs2-0069" title="WhiteNJ , NostenF , LooareesuwanS , WatkinsWM , MarshK , SnowRW , et al. Averting a malaria disaster. The Lancet1999;353(9168):1965‐7. ">White 1999</a>), and the current recommendation is for three days of the artemisinin‐derivative to cover two asexual parasite life‐cycles (<a href="./references#CD010927-bbs2-0045" title="AdjuikM , BabikerA , GarnerP , OlliaroP , TaylorW , WhiteN , et al. Artesunate combinations for treatment of malaria: meta‐analysis. The Lancet2004;363(9402):9‐17. ">Adjuik 2004</a>; <a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). </p> <p>The artemisinin derivatives also reduce the development of gametocytes (the sexual form of the <i>P. falciparum</i> parasite that is capable of infecting mosquitoes) and consequently the carriage of gametocytes in the peripheral blood (<a href="./references#CD010927-bbs2-0061" title="PriceRN , NostenF , LuxemburgerC , ter KuileFO , PaiphunL , ChongsuphajaisiddhiT , et al. Effects of artemisinin derivatives on malaria transmissibility. The Lancet1996;347(9016):1654‐8. ">Price 1996</a>; <a href="./references#CD010927-bbs2-0067" title="TargettG , DrakeleyC , JawaraM , vonSeidleinL , ColemanR , DeenJ , et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Journal of Infectious Diseases2001;183(8):1254‐9. ">Targett 2001</a>). This reduction in infectivity has the potential to reduce the post‐treatment transmission of malaria (particularly in areas of low or seasonal transmission), which may have important public health benefits (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). </p> <p>Artemisinin and its derivatives are generally reported as being safe and well‐tolerated, and the safety profile of ACTs may be largely determined by the partner drug (<a href="./references#CD010927-bbs2-0060" title="NostenF , WhiteNJ . Artemisinin‐based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene2007;77(6 Suppl):181‐92. ">Nosten 2007</a>; <a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). Animal studies of artemisinin derivatives have reported neurotoxicity (brain damage), but this has not been seen in human studies (<a href="./references#CD010927-bbs2-0062" title="PriceR , vanVugtM , PhaipunL , LuxemburgerC , SimpsonJ , McGreadyR , et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene1999;60(4):547‐55. ">Price 1999</a>). Animal studies have also shown adverse effects on the early development of the fetus, and consequently the use of artemisinin derivatives in pregnant women has so far been restricted to the second and third trimesters and continues to be evaluated (<a href="./references#CD010927-bbs2-0060" title="NostenF , WhiteNJ . Artemisinin‐based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene2007;77(6 Suppl):181‐92. ">Nosten 2007</a>). Other reported adverse events include gastrointestinal (GI) disturbance (stomach upset), dizziness, tinnitus (ringing in the ears), neutropenia (low levels of white blood cells), elevated liver enzymes (a marker for liver damage), and electrocardiographic (ECG) abnormalities (changes in cardiac conduction) (<a href="./references#CD010927-bbs2-0060" title="NostenF , WhiteNJ . Artemisinin‐based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene2007;77(6 Suppl):181‐92. ">Nosten 2007</a>). The incidence of type 1 hypersensitivity (allergic) reactions is reported to be approximately 1 in 3000 patients (<a href="./references#CD010927-bbs2-0060" title="NostenF , WhiteNJ . Artemisinin‐based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene2007;77(6 Suppl):181‐92. ">Nosten 2007</a>). </p> <p>Piperaquine is a bisquinoline antimalarial whose mode of action is thought to be similar to that of chloroquine (a 4‐aminoquinolone) (<a href="./references#CD010927-bbs2-0054" title="KeatingGM . Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs2012;72(7):937‐61. ">Keating 2012</a>). In vitro studies have shown it is effective against chloroquine‐resistant <i>P. falciparum,</i> although there are reports of some cross‐resistance (<a href="./references#CD010927-bbs2-0054" title="KeatingGM . Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs2012;72(7):937‐61. ">Keating 2012</a>). Piperaquine has a very long elimination half‐life of between two to three weeks, similar to mefloquine but longer than lumefantrine or amodiaquine, and consequently could be expected to provide a long period of post‐treatment prophylaxis (<a href="./references#CD010927-bbs2-0048" title="DavisTM , HungTY , SimIK , KarunajeewaHA , IlettKF . Piperaquine: a resurgent antimalarial drug. Drugs2005;65(1):75‐87. ">Davis 2005</a>; <a href="./references#CD010927-bbs2-0054" title="KeatingGM . Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs2012;72(7):937‐61. ">Keating 2012</a>). </p> <p>In a previous review of DHA‐P, <a href="./references#CD010927-bbs2-0058" title="MyintHY , AshleyEA , DayNP , NostenF , WhiteNJ . Efficacy and safety of dihydroartemisinin‐piperaquine. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(9):858‐66. ">Myint 2007</a> noted an association between DHA‐P and prolongation of the QT interval in two small observational trials (<a href="./references#CD010927-bbs2-0053" title="KarunajeewaH , LimC , HungTY , IlettKF , DenisMB , SocheatD , et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. British Journal of Clinical Pharmacology2004;57(1):93‐9. ">Karunajeewa 2004</a>: N = 62, and <a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a>; N = 32). Prolonged QT interval is a cardiac conduction defect which can sometimes lead to fatal arrhythmias. </p> <section id="CD010927-sec-0027"> <h4 class="title">Assessment of antimalarial drug efficacy</h4> <p>The WHO recommends that first‐line antimalarials should have a treatment failure rate of less than 10%, and that failure rates higher than 10% should trigger a change in treatment policy (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). Treatment failure can be classified as: </p> <p>Early treatment failure:</p> <p> <ul id="CD010927-list-0001"> <li> <p>the development of danger signs or severe malaria on days 1, 2, or 3 in the presence of parasitaemia; </p> </li> <li> <p>parasitaemia on day 2 higher than on day 0;</p> </li> <li> <p>parasitaemia and axillary temperature &gt; 37.5 °C on day three;</p> </li> <li> <p>parasitaemia on day 3 &gt; 20% of count on day 0.</p> </li> </ul> </p> <p>or late treatment failure:</p> <p> <ul id="CD010927-list-0002"> <li> <p>development of danger signs, or severe malaria, after day three with parasitaemia;</p> </li> <li> <p>presence of <i>P. falciparum</i> parasitaemia and axillary temperature &gt; 37.5 °C on or after day 4; </p> </li> <li> <p>presence of <i>P. falciparum</i> parasitaemia after day 7. </p> </li> </ul> </p> <p>The late reappearance of <i>P. falciparum</i> parasites in the blood can be due to failure of the drug to completely clear the original parasite (a recrudescence) or due to a new infection, which is especially common in areas of high transmission. A molecular genotyping technique called polymerase chain reaction (PCR) can be used in clinical trials to distinguish between recrudescence and new infection, giving a clearer picture of the efficacy of the drug and its post‐treatment prophylactic effect (<a href="./references#CD010927-bbs2-0070" title="WhiteNJ . The assessment of antimalarial drug efficacy. Trends in Parasitology2002;18(10):458‐64. ">White 2002</a>; <a href="./references#CD010927-bbs2-0047" title="CattamanchiA , KyabayinzeD , HubbardA , RosenthalPJ , DorseyG . Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp‐1, msp‐2, and glurp. American Journal of Tropical Medicine and Hygiene2003;68(2):133‐9. ">Cattamanchi 2003</a>). </p> <p>The WHO recommends a minimum follow‐up period of 28 days for antimalarial efficacy trials, but longer follow‐up may be required for antimalarials with long elimination half‐lives (<a href="./references#CD010927-bbs2-0070" title="WhiteNJ . The assessment of antimalarial drug efficacy. Trends in Parasitology2002;18(10):458‐64. ">White 2002</a>; <a href="./references#CD010927-bbs2-0046" title="BlolandPB . Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003. ">Bloland 2003</a>). This is because treatment failure due to true recrudescence of malaria parasites may be delayed until the drug concentration falls below the minimum concentration required to inhibit parasite multiplication, which may be beyond 28 days. The WHO recommends 42 days follow‐up for trials involving lumefantrine and piperaquine and 63 days for mefloquine trials (<a href="./references#CD010927-bbs2-0071" title="WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. ">WHO 2010</a>). </p> </section> </section> <section id="CD010927-sec-0028"> <h3 class="title" id="CD010927-sec-0028">Why it is important to do this review</h3> <p>This review aims to assist national decision‐making by providing a concise summary of the benefits and harms of DHA‐P in comparison to the other recommended ACTs. Other information that is also important when selecting national first or second‐line ACTs includes: </p> <p> <ul id="CD010927-list-0003"> <li> <p>the appropriateness of the partner drug within a locality, based on regional and national overviews of drug resistance and the intensity of malaria transmission; </p> </li> <li> <p>the simplicity of the treatment regimen (co‐formulated products are generally preferred as they reduce the availability and use of monotherapy, which may in turn reduce the development of resistance); and </p> </li> <li> <p>the cost (since the ACT is likely to represent a large percentage of the annual health expenditure in highly endemic countries). </p> </li> </ul> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010927-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010927-sec-0029"></div> <p>To evaluate the effectiveness and safety of DHA‐P compared to other ACTs for the treatment of uncomplicated <i>P. falciparum</i> malaria in adults and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010927-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010927-sec-0030"></div> <section id="CD010927-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010927-sec-0032"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs). We excluded quasi‐RCTs.</p> </section> <section id="CD010927-sec-0033"> <h4 class="title">Types of participants</h4> <p>Adults and children (including pregnant women and infants) with symptomatic, microscopically confirmed, uncomplicated <i>P. falciparum</i> malaria. </p> <p>We also included trials that recruited participants with <i>P. vivax</i> co‐infection. </p> </section> <section id="CD010927-sec-0034"> <h4 class="title">Types of interventions</h4> <section id="CD010927-sec-0035"> <h5 class="title">Intervention</h5> <p>A three‐day course of DHA‐P.</p> </section> <section id="CD010927-sec-0036"> <h5 class="title">Control</h5> <p>A three‐day course of an alternative WHO recommended ACT.</p> </section> </section> <section id="CD010927-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD010927-sec-0038"> <h5 class="title">Primary outcomes</h5> <p>Total failure at days 28, 42, and 63; PCR‐adjusted and PCR‐unadjusted.</p> </section> <section id="CD010927-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010927-list-0004"> <li> <p>Gametocyte carriage at day 7 or 14 (preference for day 14 in data analyses);</p> </li> <li> <p>Gametocyte development (negative at baseline and positive at follow‐up);</p> </li> <li> <p>Change in haemoglobin from baseline (minimum 28 day follow‐up).</p> </li> </ul> </p> <section id="CD010927-sec-0040"> <h6 class="title">Adverse events</h6> <p> <ul id="CD010927-list-0005"> <li> <p>Deaths occurring during follow‐up;</p> </li> <li> <p>Serious adverse events (life threatening, causing admission to hospital, or discontinuation of treatment); </p> </li> <li> <p>Haematological and biochemical adverse effects (for example, neutropenia, liver toxicity);</p> </li> <li> <p>Early vomiting;</p> </li> <li> <p>Other adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD010927-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010927-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 29 July 2013 using the search terms detailed in <a href="#CD010927-tbl-0002">Table 1</a>: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) published in <i>The Cochrane Library</i> ; MEDLINE; EMBASE; LILACS. We also examined the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) using the search terms 'malaria' and 'arte* OR dihydroarte*'. </p> <div class="table" id="CD010927-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Search set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CIDG SR<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CENTRAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> MEDLINE<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> EMBASE<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> LILACS<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq$</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem$</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 10 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 10 to human</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Cochrane Infectious Diseases Group Specialized Register.<br/> <sup>b</sup>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<a href="./references#CD010927-bbs2-0055" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Lefebvre 2008</a>); upper case: MeSH or EMTREE heading; lower case: free text term. </p> </div> </div> </section> <section id="CD010927-sec-0043"> <h4 class="title">Searching other resources</h4> <p>We contacted individual researchers working in the field, organizations including the WHO, and pharmaceutical companies involved in the manufacture of DHA‐P (Atlantic, Guilin, Holleykin, HolleyPharm) for information on unpublished trials. In addition, reference lists of all trials identified by the methods described above were checked. </p> </section> </section> <section id="CD010927-sec-0044"> <h3 class="title" id="CD010927-sec-0044">Data collection and analysis</h3> <section id="CD010927-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Babalwa Zani (BZ) and Michael Gathu (MG) independently reviewed the results of the literature search, obtained full‐text copies of all potentially relevant trials and checked each trial report for evidence of multiple publications from the same data set. </p> <p>BZ and MG also independently assessed each trial for inclusion using an eligibility form based on the inclusion criteria and resolved any disagreements through discussion or, where necessary, by consultation with David Sinclair (DS). We contacted trial authors when further information was necessary. We listed the ineligible trials and the reasons for their exclusion in the '<a href="./references#CD010927-sec-0113" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD010927-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>BZ and MG independently extracted data on trial characteristics including methods, participants, interventions, outcomes, dose, and drug ratios of the combinations using a pre‐tested data extraction form. We also recorded the number of participants randomized and analysed in each treatment group for each outcome and reported the loss to follow‐up in each group. </p> <p>For dichotomous outcomes, we recorded the number of participants experiencing the event and the total number of participants in each treatment group. For continuous outcomes, the arithmetic means and standard deviations for each treatment group together with the numbers of participants in each group were extracted. Where trials reported the data using geometric means, we recorded this information and extracted standard deviations on the log scale. Where trials gave median values, we extracted medians and ranges. </p> <section id="CD010927-sec-0047"> <h5 class="title">Primary outcome</h5> <p>Our primary analyses drew on the WHO's protocol for assessing and monitoring antimalarial drug efficacy (<a href="./references#CD010927-bbs2-0046" title="BlolandPB . Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003. ">Bloland 2003</a>). This protocol has been used to guide most efficacy trials since its publication in 2003, even though it was designed to assess the level of antimalarial resistance in the study area rather than for comparative trials. As a consequence, a high number of randomized participants are excluded from the final efficacy outcome as losses to follow‐up or voluntary or involuntary withdrawals. For this reason we conducted a series of sensitivity analyses to restore the integrity of the randomization process and test the robustness of the results to this methodology (For a summary of the methodology and sensitivity analysis see <a href="#CD010927-tbl-0003">Table 2</a>). </p> <div class="table" id="CD010927-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measure (Total failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR<sup>b</sup>‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Numerator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Numerator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Denominator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Primary analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusions after enrolment<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing or indeterminate PCR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 1<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Primary analysis' except: missing or indeterminate PCR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 2<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 1' except: new infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 3<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 2' except: exclusions after enrolment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 4<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 2' except: exclusions after enrolment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Note: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations.<br/> <sup>b</sup>PCR: polymerase chain reaction.<br/> <sup>c</sup>'Excluded' means removed from the calculation.<br/> <sup>d</sup>To re‐classify all indeterminate or missing PCR results as treatment failures in the PCR‐adjusted analysis.<br/> <sup>e</sup>To re‐classify all PCR‐confirmed new infections as treatment successes in the PCR‐adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have proceeded to develop a recrudescence after the new infection.)<br/> <sup>f</sup>To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR‐unadjusted total failure, this represents a true worse‐case scenario.<br/> <sup>g</sup>To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes. </p> </div> </div> <section id="CD010927-sec-0048"> <h6 class="title">PCR‐unadjusted total failure</h6> <p>We calculated PCR‐unadjusted total failure (<i>P. falciparum</i>) as the sum of early treatment failures and late treatment failures (without PCR adjustment). The denominator excluded participants for whom an outcome was not available (for example, those who were lost to follow‐up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who were found not to fulfil the inclusion criteria after randomization. </p> </section> <section id="CD010927-sec-0049"> <h6 class="title">PCR‐adjusted total failure</h6> <p>We defined PCR‐adjusted total failure (<i>P. falciparum</i>) as the sum of early treatment failures, and late treatment failures due to PCR‐confirmed recrudescence. Participants with indeterminate PCR results, missing PCR results, or PCR‐confirmed new infections were treated as involuntary withdrawals and excluded from the calculation. The denominator excluded participants for whom an outcome was not available (for example, those who were lost to follow‐up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who did not fulfil the inclusion criteria after randomization. </p> <p>These primary outcomes relate solely to failure due to <i>P. falciparum</i> . For both PCR‐unadjusted and PCR‐adjusted total failure, we retained participants who developed confirmed P. vivax infection during follow‐up in the calculation if they were treated with chloroquine and continued in follow‐up. They were classified as treatment successes if they did not subsequently develop <i>P. falciparum</i> parasitaemia. We excluded from the calculation those participants who developed <i>P. vivax</i> parasitaemia and were removed from the trial's follow‐up. </p> </section> </section> </section> <section id="CD010927-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>BZ and MG independently assessed the risk of bias for each trial using 'The Cochrane Collaboration's tool for assessing the risk of bias' (<a href="./references#CD010927-bbs2-0051" title="HigginsJPT , Altman DG(editors) . Chapter 8:  Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Interventions. Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. Chichester: John Wiley &amp; Sons Ltd. ">Higgins 2008</a>) and resolved differences of opinion through discussion with DS. We followed the guidance to assess whether adequate steps were taken to reduce the risk of bias across six domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias. </p> <p>For sequence generation and allocation concealment, we reported the methods used. For blinding, we described who was blinded and the blinding method. For incomplete outcome data, we reported the percentage and proportion of participants lost to follow‐up. For selective outcome reporting, any discrepancies between the methods used and the results were stated in terms of the outcomes measured or the outcomes reported. For other biases, we described any other trial features that could have affected the trial result (for example, if the trial was stopped early). </p> <p>We categorized our risk of bias judgements as 'low', 'high', or 'unclear'. Where risk of bias was unclear, we attempted to contact the trial authors for clarification and resolved any differences of opinion through discussion. </p> </section> <section id="CD010927-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the data using <a href="./references#CD010927-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013. ">Review Manager (RevMan)</a> and presented and combined dichotomous data using risk ratios (RR). For continuous data summarized by arithmetic means and standard deviations, we combined data using mean differences. RRs and mean differences were accompanied by 95% confidence intervals (CI). We reported medians and ranges in tables. </p> </section> <section id="CD010927-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We split trials including more than two comparison groups and analysed as individual pair‐wise comparisons. When conducting meta‐analysis, we ensured that participants and cases in the placebo group were counted only once, by dividing the placebo cases and participants evenly between the intervention groups. </p> </section> <section id="CD010927-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>If data from the trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information. If the missing data rendered the result uninterpretable, we excluded the data from the meta‐analysis and clearly stated the reason for exclusion. We explored the potential effects of missing data through a series of sensitivity analyses (<a href="#CD010927-tbl-0003">Table 2</a>). </p> </section> <section id="CD010927-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by inspecting the forest plots, applying the Chi² test with a 10% level of statistical significance, and using the I² statistic with a value of 50% to denote moderate levels of heterogeneity. </p> </section> <section id="CD010927-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>The possibility of publication bias was assessed by examining funnel plots for asymmetry. We noted that funnel plot asymmetry could also be caused by differences in methodological quality or heterogeneity. </p> </section> <section id="CD010927-sec-0056"> <h4 class="title">Data synthesis</h4> <p>To aid interpretation, we gave the included trials identity codes including the first author, the year of publication, and the three‐letter international country code or two‐letter continent code (for trials conducted in more than one country). We listed trials in forest plots in chronological order of the year the trial was completed. </p> <p>Using pair‐wise comparisons we directly compared treatments. For outcomes that were measured at different time points, we stratified the analysis by the time point. The primary outcome analysis was also stratified by geographical region as a crude marker for differences in transmission and resistance patterns. </p> <p>We performed meta‐analysis within geographic regions where appropriate after assessment and investigation of heterogeneity. In the first instance, we used a fixed‐effects model and applied a random‐effects model when the Chi² test P value was less than 0.1 or the I² statistic greater than 50%. </p> <section id="CD010927-sec-0057"> <h5 class="title">Quality of evidence</h5> <p>We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across studies has four levels: high, moderate, low, or very low. RCTs are initially categorized as high quality but can be downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias. Similarly, observational studies are initially categorized as low quality and can be downgraded by the same criteria, but in exceptional circumstances may be upgraded by three further criteria; large effect size, all plausible confounders would act to reduce the effect size, and evidence of a dose‐response effect (<a href="./references#CD010927-bbs2-0050" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchünemannHJ , et al. What is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. '>Guyatt 2008</a>). </p> </section> </section> <section id="CD010927-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated potential sources of heterogeneity through a series of analyses, sub‐grouping the trials by: geographical region, intensity of malaria transmission (low to moderate versus high malaria transmission), known parasite resistance, allocation concealment, participant age, and drug dose (comparing regimens where there are significant variations in drug dose). </p> </section> <section id="CD010927-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a series of sensitivity analyses to investigate the robustness of the methodology used in the primary analysis. The aim was to restore the integrity of the randomization process by adding excluded groups back into the analysis in a stepwise fashion (see <a href="#CD010927-tbl-0003">Table 2</a> for details). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010927-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010927-sec-0060"></div> <section id="CD010927-sec-0061"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#CD010927-sec-0112" title="">Characteristics of included studies</a> and <a href="./references#CD010927-sec-0113" title="">Characteristics of excluded studies</a> section. </p> <section id="CD010927-sec-0062"> <h4 class="title">Results of the search</h4> <p>We conducted the searches up to 29 July 2013 and identified 90 trials in total. After screening titles and abstracts, we obtained full text copies of 49 trials. Of these, 34 trials met the inclusion criteria and we excluded 15 trials (<a href="#CD010927-fig-0001">Figure 1</a>). We included 27 trials as primary references and retained seven trials as secondary references for additional data on secondary outcomes and adverse events. One of the 26 trials had two different recruitment settings which we split and considered as two separate trials (<a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a>; <a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a>). One trial (<a href="./references#CD010927-bbs2-0042" title="BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. ">Borrmann 2011 KEN (a)</a>) is pending as we await data for a separate recruitment period from the trial authors. </p> <div class="figure" id="CD010927-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010927-sec-0063"> <h4 class="title">Included studies</h4> <p>We included 27 trials, enrolling 16,382 participants and conducted between 2002 and 2010. </p> <p>Twelve trials were conducted in Africa; Uganda (three trials), Kenya (three trials), Sudan (one trial), Rwanda (one trial), Burkina Faso (one trial), and three multi‐centre trials with sites in Kenya, Uganda, Rwanda, Mozambique, Zambia, Gabon, Burkina Faso, Nigeria, Senegal, Côte d’Ivoire, and Cameroon (<a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a>; <a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>; <a href="./references#CD010927-bbs2-0025" title="YavoW , FayeB , KueteT , DjohanV , OgaSA , KassiRR , et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin‐piperaquine compared to artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub‐Saharan Africa. Malaria Journal2011;10(198):1‐8. ">Yavo 2011 AF</a>). Fourteen trials were conducted in Asia and Oceania; Thailand (five trials), Myanmar (two trials), Laos (one trial), Vietnam (one trial), Cambodia (one trial), Indonesia (two trials), Papua New Guinea (one trial); and one multi‐centre trial had sites in Thailand, Laos, and India (<a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>). Only one trial was from South America (Peru). </p> <p>The African trials focused on children, while Asian trials included older populations and excluded children below one year of age. All trials excluded pregnant and lactating women. </p> <p>Eleven trials compared DHA‐P with AS+MQ, 16 trials compared DHA‐P with AL, four trials compared DHA‐P with ASAQ, and one trial compared DHA‐P with AS+SP. Some trials had more than two arms and compared multiple ACTs. </p> <p>Three trials (<a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a>; <a href="./references#CD010927-bbs2-0017" title="RatcliffA , SiswantoroH , KenangalemE , MaristelaR , WuwungRM , LaihadF , et al. Two fixed‐dose artemisinin combinations for drug‐resistant falciparum and vivax malaria in Papua, Indonesia: an open‐label randomised comparison. The Lancet2007;369(9563):757‐65. ">Ratcliff 2007 IDN</a>; <a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a>) conducted in Asia and Oceania included participants with <i>P. vivax</i> mono‐infection at baseline. For our primary analysis we obtained data from the trial authors for only those participants who had <i>P. falciparum</i> or mixed infection (<i>P. falciparum</i> and <i>P. vivax</i>) at baseline. <a href="./references#CD010927-bbs2-0003" title="ArinaitweE , SandisonTG , WanziraH , KakuruA , HomsyJ , KalamyaJ , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clinical Infectious Diseases2009;49(11):1629‐37. CreekD , BigiraV , ArinaitweE , WanziraH , KakuruA , TapperoJ , et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin‐piperaquine compared with artemether‐lumefantrine for uncomplicated malaria. American Journal of Tropical Medicine and Hygiene2010;83(4):873‐5. KakuruA , JagannathanP , ArinaitweE , WanziraH , MuhindoM , BigiraV , et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. American Journal of Tropical Medicine and Hygiene2013;88(4):736‐43. KatrakS , GasasiraA , ArinaitweE , KakuruA , WanziraH , BigiraV , et al. Safety and tolerability of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for malaria in young HIV‐infected and uninfected children. Malaria Journal2009;8(272):1‐8. ">Arinaitwe 2009 UGA</a> had an unusual trial design where participants were followed up for more than one episode of malaria. We used data from all malaria episodes in our primary analysis. </p> <p>We listed the trial details of the included studies in the '<a href="./references#CD010927-sec-0112" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD010927-sec-0064"> <h4 class="title">Excluded studies</h4> <p>The reasons for exclusion are in the '<a href="./references#CD010927-sec-0113" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD010927-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>For a summary of the 'Risk of bias' assessments, see <a href="#CD010927-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD010927-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD010927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD010927-sec-0066"> <h4 class="title">Allocation</h4> <p>Nine trials were at low risk of selection bias, with adequate methods for both generation of the randomization sequence and allocation concealment. A further 18 studies were at unclear risk of selection bias due to inadequate descriptions of their methods. For primary outcomes we conducted a sensitivity analysis including only the trials with adequate allocation concealment. </p> </section> <section id="CD010927-sec-0067"> <h4 class="title">Blinding</h4> <p>Eighteen trials blinded the microscopists to treatment allocation and so were at low risk of performance and detection bias for the primary outcomes. Only four of the included trials blinded the outcome assessors for adverse events. </p> </section> <section id="CD010927-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>We reported the proportion of participants in each treatment arm for whom an outcome was not available and conducted sensitivity analyses to test the possible effect of these losses. Four trials were at high risk of bias due to high dropout rates (&gt; 15%). </p> </section> <section id="CD010927-sec-0069"> <h4 class="title">Selective reporting</h4> <p>Due to the varying half‐lives of drugs, the choice of which day to measure outcomes can influence the comparative effects of the ACTs. If an ACT with a long half‐life (DHA‐P or AS+MQ) is compared to a drug with a short half‐life (AS+AQ or AS+SP), day 28 outcomes may underestimate PCR‐adjusted failure with the long half‐life drug. At later time points (day 42 and 63), drugs with long half‐lives are likely to appear superior in preventing new infections (PCR‐unadjusted failure) which represents a prophylactic effect. We noted this while interpreting the data but did not consider this a source of trial bias. </p> </section> <section id="CD010927-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Pharmaceutical companies provided financial support or study drugs in 13 trials. In the two large trials of the new Eurartesim® formulation (<a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> &amp; <a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>), the pharmaceutical company was fully involved in the design, conduct and analysis of the trials, In one of these (<a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a>), it is stated that an independent author had access to the primary dataset and took responsibility for the analyses. We judged this trial to be at unclear risk of bias. In the second trial, this additional safety measure was not described and we judged the trial to be at high risk of bias. </p> </section> </section> <section id="CD010927-sec-0071"> <h3 class="title" id="CD010927-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD010927-tbl-0001"><b>Summary of findings for the main comparison</b> Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated <i>P. falciparum</i> malaria in Africa</a> </p> <section id="CD010927-sec-0072"> <h4 class="title">Comparison 1. DHA‐P versus artesunate plus mefloquine</h4> <p>We found 11 trials, 10 in Asia and one in South America, that assessed this comparison; conducted between 2002 and 2009. </p> <p>Allocation concealment was at 'low risk of bias' in only two trials (<a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a>; <a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a>). Five trials blinded laboratory staff (outcome assessors) to treatment allocation (<a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a>; <a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a>; <a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a>; <a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a>; <a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>). Patients were unblinded in all trials, and only one trial blinded outcome assessors for adverse effects (<a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>). </p> <section id="CD010927-sec-0073"> <h5 class="title">Total failure</h5> <p>In Asia over 63 days follow‐up, recurrent parasitaemias (including both recrudescences and new infections) occurred in less than 15% of all participants, with no differences in PCR‐unadjusted treatment failure between groups (day 28: eight trials, 3487 participants, <a href="./references#CD010927-fig-0003" title="">Analysis 1.1</a>; day 42: seven trials, 3421 participants, <a href="./references#CD010927-fig-0005" title="">Analysis 1.3</a>; Day 63: five trials, 2715 participants, <a href="./references#CD010927-fig-0007" title="">Analysis 1.5</a>). </p> <p>Once adjusted by PCR to exclude new infections, treatment failure at day 28 was below 5% for both ACTs in all eight trials for which data was available (eight trials, 3482 participants, <a href="./references#CD010927-fig-0004" title="">Analysis 1.2</a>). Two of the eight trials, conducted in Thailand at trial sites with multi‐drug resistant <i>P. falciparum</i>, found slightly higher levels of recrudescence following AS+MQ and statistically significant benefits with DHA‐P (<a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a>; <a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>). Recrudescences remained low in both groups over 63 days of follow‐up (day 42: six trials, 2901 participants, <a href="./references#CD010927-fig-0006" title="">Analysis 1.4</a>; day 63: five trials, 2500 participants, <a href="./references#CD010927-fig-0008" title="">Analysis 1.6</a>). </p> <p>In the one trial from South America, only day 63 data was available (<a href="./references#CD010927-fig-0007" title="">Analysis 1.5</a>; <a href="./references#CD010927-fig-0008" title="">Analysis 1.6</a>). Recrudescences and new infections were very rare with both treatments, but new infections were lower with AS+MQ (RR 6.19, 95% CI 1.40 to 27.35, one trial, 445 participants, <a href="./references#CD010927-fig-0007" title="">Analysis 1.5</a>). </p> </section> <section id="CD010927-sec-0074"> <h5 class="title">Gametocytes</h5> <p>AS+MQ appears to clear gametocytes from the peripheral blood quicker than DHA‐P (Gametocyte carriage on Day 7: RR 1.99, 95% CI 1.57 to 2.51, three trials, 2270 participants, <a href="./references#CD010927-fig-0009" title="">Analysis 1.7</a>; Day 14: RR 5.11, 95% CI 3.26 to 7.99, three trials, 2249 participants, <a href="./references#CD010927-fig-0009" title="">Analysis 1.7</a>). In addition, the number of participants who developed detectable gametocytes (after being negative at baseline) was low in both groups, but lowest with AS+MQ (RR 3.06, 95% CI 1.13 to 8.33, three trials, 1234 participants, <a href="./references#CD010927-fig-0010" title="">Analysis 1.8</a>). Five trials reported additional data on gametocyte carriage which could not be pooled and are presented in <a href="#CD010927-tbl-0004">Table 3</a>. </p> <div class="table" id="CD010927-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">DHA‐P versus AS+MQ: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with gametocytes at any timepoint after treatment (on or after day 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean across all groups was 0.10 (95% CI 0.03 to 0.20). No difference between groups (published data). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte incidence at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte incidence at day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte carriage in DHA‐P group was higher than in AS+MQ group (published data). Figures not given. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for fixed‐dose AS+MQ combination.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2</p> <p>(130/6420)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> <p>(23/3108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Published data in paper presented as "person gametocytemia weeks per 100 person weeks".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median decrease in HCT by day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean decrease in HCT up to day 7 then recovery in all groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute changes in HCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean decrease in HCT up to day 7 then recovery in all groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0010" title="JanssensB , vanHerpM , GoubertL , ChanS , UongS , NongS , et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health2007;12(2):251‐9. ">Janssens 2007 KHM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean HCT at day 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 % (3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2% (3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in both treatment groups showed similar haematological<br/> recovery during the 63‐day follow‐up period". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean HCT days 7 to 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"the mean hematocrit after treatment did not significantly differ between groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean haemoglobin at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for supervised treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion anaemic (Hb &lt; 10 g/dL) on day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for supervised treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean increase in haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The mean increase of haemoglobin was similar among the treatment groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean increase in Hb from day 0 to day 63 in g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 ± 2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 ± 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Hb ‐ Haemoglobin<br/> HCT ‐ Haematocrit </p> </div> </div> </section> <section id="CD010927-sec-0075"> <h5 class="title">Anaemia</h5> <p>Seven trials reported a variety of measures of haematological changes between baseline and the last day of follow‐up which we could not pool. None of the individual trials reported differences between groups (see <a href="#CD010927-tbl-0004">Table 3</a>). </p> </section> <section id="CD010927-sec-0076"> <h5 class="title">Adverse events</h5> <p>There was no difference in the frequency of serious adverse events (eight trials, 3522 participants, <a href="./references#CD010927-fig-0011" title="">Analysis 1.9</a>; see <a href="./appendices#CD010927-sec-0106">Appendix 2</a> for details of serious adverse events). </p> <p>Nine trials reported some measure of early vomiting (vomiting related to drug administration) and there was no difference shown in any trial (nine trials, 4114 participants, <a href="./references#CD010927-fig-0012" title="">Analysis 1.10</a>). However, subsequent nausea and vomiting were consistently more common with AS+MQ (Nausea: RR 0.68, 95% CI 0.60 to 0.78, nine trials, 4531 participants; vomiting: RR 0.59, 95% CI 0.47 to 0.75, five trials, 2744 participants, <a href="./references#CD010927-fig-0012" title="">Analysis 1.10</a>). Diarrhoea was more common with DHA‐P (RR 1.46, 95% CI 1.05 to 2.04, five trials, 2217 participants, <a href="./references#CD010927-fig-0012" title="">Analysis 1.10</a>). </p> <p>AS+MQ was consistently associated with increased dizziness (RR 0.72, 95% CI 0.66 to 0.78, nine trials, 4531 participants), and sleeplessness (RR 0.49, 95% CI 0.40 to 0.60, six trials, 2551 participants, <a href="./references#CD010927-fig-0013" title="">Analysis 1.11</a>), and increases in headache (four trials), fatigue (two trials), nightmares (one trial), and anxiety (one trial) are reported in the few trials that recorded them (<a href="./references#CD010927-fig-0013" title="">Analysis 1.11</a>). </p> <p>Palpitations were also more common with AS+MQ (RR 0.61, 95% CI 0.45 to 0.82, three trials, 1175 participants, <a href="./references#CD010927-fig-0014" title="">Analysis 1.12</a>), but only one trial performed routine ECGs in both treatment groups (<a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>). In this trial there was a baseline imbalance in the prevalence of borderline prolonged QTc (431 to 450 ms in children and adult men/451 to 470 ms in adult women), using Bazett's correction method (16.6% DHA‐P versus 12.2% AS+MQ, P = 0.066; authors' own figures), but not Fridericia's method (2.9% DHA‐P versus 1.6% AS+MQ, P &gt; 0.05; authors' own figures). </p> <p>On day 2, a higher proportion of participants treated with DHA‐P had borderline prolonged QTc by both correction methods (Bazett's: 21.4% DHA‐P versus 16.3% AS+MQ, P = 0.043; Fridericia's: 13.0% DHA‐P versus 5.3% AS+MQ, P &lt; 0.001; authors' own figures). There was also a statistically significant increase in the prevalence of prolonged QTc with DHA‐P (&gt; 450 ms in children and adult men, and &gt; 470 ms in adult women), using Bazett's method but not Fridericia's method (one trial, 1148 participants, <a href="./references#CD010927-fig-0014" title="">Analysis 1.12</a>). No consequent arrhythmias were noted, and these differences were no longer present at day seven (for additional data see <a href="#CD010927-tbl-0005">Table 4</a>). </p> <div class="table" id="CD010927-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">DHA‐P versus AS+MQ/AL6: QTc measurements</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correction<br/> method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431 to 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.066</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431 to 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.043</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prolonged QTc (&gt; 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc increase &gt; 60 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AL6<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>1553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Borderline QTc (431‐450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431‐450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prolonged QTc (&gt; 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc &gt; 500 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc increase &gt; 60 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> In this analysis the direction of effect is reversed. These figures have been confirmed as correct by the study authors.<br/> <sup>2</sup> Figures not presented in paper: Taken from <a href="./references#CD010927-fig-0038" title="">Analysis 4.13</a>.<br/> N/R ‐ Not reported<br/> QTcB ‐ QT interval corrected for rate and gender using Bazett's method.<br/> QTcF ‐ Qt interval corrected for rate and gender using Fridericia's method. </p> </div> </div> <p>Four trials conducted biochemical monitoring for either renal or hepatic adverse events. Monitoring was adequate in three trials (<a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a>; <a href="./references#CD010927-bbs2-0023" title="TranTH , DolecekC , PhamPM , NguyenTD , NguyenTT , LeHT , et al. Dihydroartemisinin‐piperaquine against multidrug‐resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. The Lancet2004; Vol. 363, issue 9402:18‐22. ">Tran 2004 VNM</a>; <a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a>), and inadequate in one (<a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a>), but incompletely reported in all four trials. No clinically important toxicities were reported (see <a href="#CD010927-tbl-0006">Table 5</a>). </p> <div class="table" id="CD010927-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">DHA‐P versus AS+MQ: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate to detect adverse events?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U&amp;E, LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No biochemical evidence of toxicity was observed".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U&amp;E, LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No patient had abnormal liver and renal function test results of clinical significance, both at entry and at day 7". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0023" title="TranTH , DolecekC , PhamPM , NguyenTD , NguyenTT , LeHT , et al. Dihydroartemisinin‐piperaquine against multidrug‐resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. The Lancet2004; Vol. 363, issue 9402:18‐22. ">Tran 2004 VNM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 3,7,28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no significant differences between the three groups in the results of liver function tests done on all patients on days 3, 7, and 28". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0, 28, 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Other than elevated liver parameters, as might be expected in this population, there were no relevant changes in biochemistry parameters".' </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Judged as adequate given that no clinically important abnormalities were seen at day 7. Longer follow‐up is therefore probably unnecessary.<br/> <sup>2</sup> Judged as incomplete as data were not presented. Only a text summary was given.<br/> <sup>3</sup> Judged as inadequate as biochemical abnormalities are likely to occur earlier than day 28. </p> <p>LFT = Liver Function Tests</p> <p>U&amp;E = Urea and electrolytes</p> </div> </div> </section> <section id="CD010927-sec-0077"> <h5 class="title">Sensitivity analysis</h5> <p>As described in the methods section, we undertook a series of sensitivity analyses to test the robustness of our results to different analysis plans. An example of these is given in <a href="./references#CD010927-fig-0016" title="">Analysis 1.14</a> &amp; <a href="./references#CD010927-fig-0017" title="">Analysis 1.15</a>. In general, the method of analysis did not change the significance of results and so the remaining sensitivity analyses were deleted. </p> </section> </section> <section id="CD010927-sec-0078"> <h4 class="title">Comparisons 2 and 3: DHA‐P dosing concerns</h4> <p>Two dosing regimens were commonly used in clinical trials of DHA‐P versus AS+MQ, which give the same total dose, but divided into three or four doses, given over three days (see <a href="#CD010927-tbl-0007">Table 6</a>). One trial (<a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a>) directly compared the three‐dose regimen with the four‐dose regimen and found no difference at any time point (one trial, 318 participants, <a href="./references#CD010927-fig-0018" title="">Analysis 2.1</a>; <a href="./references#CD010927-fig-0019" title="">Analysis 2.2</a>). </p> <div class="table" id="CD010927-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">DHA‐P versus AS+MQ dosing regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year of study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age limits</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 14 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 65 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 65 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs or 3 divided doses at 0, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 to 60 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total dose: 6.3 mg/kg DHA and 50.4 mg/kg PQP in 3 divided doses, given once daily for 3 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0010" title="JanssensB , vanHerpM , GoubertL , ChanS , UongS , NongS , et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health2007;12(2):251‐9. ">Janssens 2007 KHM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adult total dose</b>: 6 mg/kg DHA and + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs </p> <p><b>Children total dose</b>: 6.4 mg/kg DHA + 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults</b>: 100 mg AS plus 500 mg MQ twice daily on day 0, 200 mg AS once daily on days 1 and 2. </p> <p><b>Children</b>: 4 mg/kg AS once daily for 3 days + 25 mg/kg MQ in 2 equal doses on day 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 mg/kg DHA + 50.4 mg/kg P in 3 divided doses, once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 15 mg MQ base/kg on day 1 and 10 mg base/kg on day 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 mg/kg DHA + 50.4 mg/kg P in 3 divided doses, once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days.</p> <p>25 mg MQ base/kg as a single dose on day 0.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/kg DHA + 20 mg/kg P daily, given once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fixed combination</b>: 4 mg/kg AS + 8.8 mg/kg MQ daily, once daily for 3 days. </p> <p><b>Loose combination</b>: 4 mg/kg AS once daily for 3 days + 25 mg base/kg MQ as a single dose on day 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0021" title="TangpukdeeN , KrudsoodS , ThanachartwetW , ChalermrutK , PengruksaC , SrivilairitS , et al. An open randomized clinical trial of Artekin vs artesunate‐mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health2005;36(5):1085‐91. ">Tangpukdee 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 14 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 45 mg/kg P in 3 divided doses, given once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0023" title="TranTH , DolecekC , PhamPM , NguyenTD , NguyenTT , LeHT , et al. Dihydroartemisinin‐piperaquine against multidrug‐resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. The Lancet2004; Vol. 363, issue 9402:18‐22. ">Tran 2004 VNM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg/320 mg tablets<br/> <b>Adults</b>: 2 tablets at 0, 6, 24, and 48 hrs </p> <p><b>Children &lt; 15 yrs</b>: 1 tablet at 0, 6, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 25 mg base/kg MQ as 2 divided doses 6 hrs apart on day 3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3m to 65 yrs (≥18 yrs in India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA: 2.25 mg/kg DHA + 18 mg/kg P daily dose for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4mg/kg AS once daily for 3 days + MQ none on day 0, then 15 mg/kg once on day 1 and 10 mg/kg once on day 2 </p> </td> </tr> </tbody> </table> </div> <p>In comparisons comparing DHA‐P to AS+MQ, six trials used the three‐dose regimen, four trials used the four‐dose regimen, and one trial used both. Stratifying the analysis by dosing regimen did not reveal any important differences in efficacy between the two regimens (<a href="./references#CD010927-fig-0020" title="">Analysis 3.1</a> to <a href="./references#CD010927-fig-0025" title="">Analysis 3.6</a>). </p> </section> <section id="CD010927-sec-0079"> <h4 class="title">Comparison 4. DHA‐P versus artemether‐lumefantrine (six doses)</h4> <p>We found fifteen trials which assessed this comparison; eleven in Africa, three in Asia and one in Oceania; conducted between 2005 and 2011. Eleven of the fifteen trials included children only. </p> <p>Allocation concealment was at low risk of bias in eight trials (<a href="./references#CD010927-bbs2-0011" title="KamyaMR , YekaA , BukirwaH , LugemwaM , RwakimariJB , StaedkeSG , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treatment of malaria: a randomized trial. PLoS Clinical Trials2007;2(5):e20. ">Kamya 2007 UGA</a>; <a href="./references#CD010927-bbs2-0017" title="RatcliffA , SiswantoroH , KenangalemE , MaristelaR , WuwungRM , LaihadF , et al. Two fixed‐dose artemisinin combinations for drug‐resistant falciparum and vivax malaria in Papua, Indonesia: an open‐label randomised comparison. The Lancet2007;369(9563):757‐65. ">Ratcliff 2007 IDN</a>; <a href="./references#CD010927-bbs2-0027" title="ZongoI , DorseyG , RouambaN , DokomajilarC , SéréY , RosenthalPJ , et al. Randomized comparison of amodiaquine plus sulfadoxine‐pyrimethamine, artemether‐lumefantrine, and dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clinical Infectious Diseases2007; Vol. 45, issue 11:1453‐61. ">Zongo 2007 BFA</a>; <a href="./references#CD010927-bbs2-0026" title="YekaA , DorseyG , KamyaMR , TalisunaA , LugemwaM , RwakimariJB , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One2008;3(6):e2390. ">Yeka 2008 UGA</a>; <a href="./references#CD010927-bbs2-0003" title="ArinaitweE , SandisonTG , WanziraH , KakuruA , HomsyJ , KalamyaJ , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clinical Infectious Diseases2009;49(11):1629‐37. CreekD , BigiraV , ArinaitweE , WanziraH , KakuruA , TapperoJ , et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin‐piperaquine compared with artemether‐lumefantrine for uncomplicated malaria. American Journal of Tropical Medicine and Hygiene2010;83(4):873‐5. KakuruA , JagannathanP , ArinaitweE , WanziraH , MuhindoM , BigiraV , et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. American Journal of Tropical Medicine and Hygiene2013;88(4):736‐43. KatrakS , GasasiraA , ArinaitweE , KakuruA , WanziraH , BigiraV , et al. Safety and tolerability of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for malaria in young HIV‐infected and uninfected children. Malaria Journal2009;8(272):1‐8. ">Arinaitwe 2009 UGA</a>; <a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a>; <a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>; <a href="./references#CD010927-bbs2-0025" title="YavoW , FayeB , KueteT , DjohanV , OgaSA , KassiRR , et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin‐piperaquine compared to artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub‐Saharan Africa. Malaria Journal2011;10(198):1‐8. ">Yavo 2011 AF</a>). Ten out of 14 trials blinded laboratory staff to treatment allocation. </p> <section id="CD010927-sec-0080"> <h5 class="title">Total failure</h5> <p>In Africa, PCR‐unadjusted treatment failure at day 28 was consistently lower with DHA‐P (RR 0.34, 95% CI 0.30 to 0.39, nine trials, 6200 participants, <a href="./references#CD010927-fig-0026" title="">Analysis 4.1</a>). After PCR adjustment to exclude new infections, treatment failure at Day 28 was below 5% with both ACTs in all nine trials, but was consistently lowest with DHA‐P (RR 0.42, 95% CI 0.29 to 0.62, nine trials, 5417 participants, <a href="./references#CD010927-fig-0027" title="">Analysis 4.2</a>). Six trials continued follow‐up until day 42, and two until day 63. DHA‐P appears to have a longer post‐treatment prophylactic effect than AL6 in keeping with its longer elimination half‐life (Day 42 PCR‐unadjusted treatment failure: RR 0.60, 95% CI 0.53 to 0.67, seven trials, 3301 participants, <a href="./references#CD010927-fig-0028" title="">Analysis 4.3</a>; Day 63 PCR‐unadjusted treatment failure: RR 0.71, 95% CI 0.65 to 0.78, two trials, 3200 participants, <a href="./references#CD010927-fig-0030" title="">Analysis 4.5</a>). </p> <p>In Asia and Oceania, PCR‐unadjusted treatment failure at day 28 was similar between treatments (four trials, 1143 participants, <a href="./references#CD010927-fig-0026" title="">Analysis 4.1</a>), and with no statistically significant differences after PCR adjustment (three trials, 925 participants, <a href="./references#CD010927-fig-0027" title="">Analysis 4.2</a>). Of note, PCR‐adjusted treatment failure at day 28 was above 10% in those treated with DHA‐P in the one trial from Papua New Guinea (<a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a>), but this has not been seen elsewhere. No differences were seen in PCR‐unadjusted or PCR‐adjusted treatment failure at day 42 (two trials, 572 participants, <a href="./references#CD010927-fig-0028" title="">Analysis 4.3</a>; <a href="./references#CD010927-fig-0029" title="">Analysis 4.4</a>), or day 63 (one trial, 323 participants, <a href="./references#CD010927-fig-0030" title="">Analysis 4.5</a>; <a href="./references#CD010927-fig-0031" title="">Analysis 4.6</a>). </p> </section> <section id="CD010927-sec-0081"> <h5 class="title">Gametocytes</h5> <p>SIx trials, all from Africa, reported the development of gametocytes in those negative at baseline. The results were highly heterogenous and we could not pool them (six trials, 1968 participants) heterogeneity: Chi² test, P = 0.001, I² = 78%, <a href="./references#CD010927-fig-0032" title="">Analysis 4.7</a>). Carriage of gametocytes during the first two weeks was higher with DHA‐P (RR 4.32, 95% 1.48 to 12.63, four trials, 1537 participants, <a href="./references#CD010927-fig-0033" title="">Analysis 4.8</a>), but lower with DHA‐P during weeks three to six; a finding which may reflect the lower treatment failure rates with DHA‐P at later time points (<a href="./references#CD010927-fig-0033" title="">Analysis 4.8</a>). <a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> reports that person‐gametocyte weeks was higher in those treated with DHA‐P (see <a href="#CD010927-tbl-0008">Table 7</a>). </p> <div class="table" id="CD010927-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">DHA‐P versus AL6: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AL6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0017" title="RatcliffA , SiswantoroH , KenangalemE , MaristelaR , WuwungRM , LaihadF , et al. Two fixed‐dose artemisinin combinations for drug‐resistant falciparum and vivax malaria in Papua, Indonesia: an open‐label randomised comparison. The Lancet2007;369(9563):757‐65. ">Ratcliff 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐treatment gametocytemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0026" title="YekaA , DorseyG , KamyaMR , TalisunaA , LugemwaM , RwakimariJB , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One2008;3(6):e2390. ">Yeka 2008 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean increase in Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0016" title="MensPF , SawaP , vanAmsterdamSM , VersteegI , OmarSA , SchalligHD , et al. A randomized trial to monitor the efficacy and effectiveness by QT‐NASBA of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malaria Journal2008;7(237):1‐8. ">Mens 2008 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final mean Hb level (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.15 ± 1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.79 ± 1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0003" title="ArinaitweE , SandisonTG , WanziraH , KakuruA , HomsyJ , KalamyaJ , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clinical Infectious Diseases2009;49(11):1629‐37. CreekD , BigiraV , ArinaitweE , WanziraH , KakuruA , TapperoJ , et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin‐piperaquine compared with artemether‐lumefantrine for uncomplicated malaria. American Journal of Tropical Medicine and Hygiene2010;83(4):873‐5. KakuruA , JagannathanP , ArinaitweE , WanziraH , MuhindoM , BigiraV , et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. American Journal of Tropical Medicine and Hygiene2013;88(4):736‐43. KatrakS , GasasiraA , ArinaitweE , KakuruA , WanziraH , BigiraV , et al. Safety and tolerability of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for malaria in young HIV‐infected and uninfected children. Malaria Journal2009;8(272):1‐8. ">Arinaitwe 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Hb recovery (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 ± 1.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 ± 1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0002" title="AgarwalA , McMorrowM , OnyangoP , OtienoK , OderoC , WilliamsonJ , et al. A randomized trial of artemether‐lumefantrine and dihydroartemisinin‐piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malaria Journal2013;12(254):1‐8. ">Agarwal 2013 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Hb increase from baseline in patients not re‐infected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P value for difference in mean Hb increase in re‐infected patients and those not re‐infected is given as 0.9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Hb increase from baseline in re‐infected patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Hb ‐ Haemoglobin</p> </div> </div> <p>In Asia, <a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a> and <a href="./references#CD010927-bbs2-0017" title="RatcliffA , SiswantoroH , KenangalemE , MaristelaR , WuwungRM , LaihadF , et al. Two fixed‐dose artemisinin combinations for drug‐resistant falciparum and vivax malaria in Papua, Indonesia: an open‐label randomised comparison. The Lancet2007;369(9563):757‐65. ">Ratcliff 2007 IDN</a> report no differences in gametocyte carriage between groups but did not give figures, while <a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> reports higher gametocyte carriage with DHA‐P (see <a href="#CD010927-tbl-0008">Table 7</a>). </p> </section> <section id="CD010927-sec-0082"> <h5 class="title">Anaemia</h5> <p>Six trials reported changes in haemoglobin from baseline to the last day of follow‐up (day 28 or 42). There is a trend towards a small benefit with DHA‐P which may not be of clinical significance (six trials, 3529 participants, <a href="./references#CD010927-fig-0034" title="">Analysis 4.9</a>). </p> </section> <section id="CD010927-sec-0083"> <h5 class="title">Adverse events</h5> <p>No difference has been shown in the frequency of serious adverse events, although the trend is towards a small increase in serious adverse events with DHA‐P (nine trials, 7246 participants, <a href="./references#CD010927-fig-0035" title="">Analysis 4.10</a>, see <a href="./appendices#CD010927-sec-0106">Appendix 2</a> for details of serious adverse events). </p> <p>DHA‐P is associated with a higher frequency of early vomiting (drug‐related vomiting), which just reached statistical significance (RR 1.69, 95% CI 1.00 to 2.83, four trials, 2969 participants, <a href="./references#CD010927-fig-0036" title="">Analysis 4.11</a>), but there was no difference in vomiting overall (nine trials, 6761 participants, <a href="./references#CD010927-fig-0036" title="">Analysis 4.11</a>). </p> <p>Compared to AL6, DHA‐P was also associated with a slightly higher frequency of pruritis (RR 1.74, 95% CI 1.03 to 2.92, five trials, 2033 participants, <a href="./references#CD010927-fig-0039" title="">Analysis 4.14</a>), but there were no differences in any other clinical side effects (<a href="./references#CD010927-fig-0036" title="">Analysis 4.11</a> to <a href="./references#CD010927-fig-0039" title="">Analysis 4.14</a>). </p> <p>Only one trial conducted ECG monitoring on participants in both treatment groups (<a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a>). On day 2, a higher proportion of participants treated with DHA‐P had borderline raised QTc intervals (431 to 450 ms) when corrected by Bazett's method (29.1% DHA‐P versus 19.8% AL6, P &lt; 0.001; authors' own figures), but not Fridericia's method (1.0% DHA‐P versus 1.2% AL6, P = 0.76; authors' own figures). There were no differences in the proportion of patients with prolonged QTc interval (&gt; 450 ms), using either Bazett's or Fridericia's method (one trial, 1548 participants, <a href="./references#CD010927-fig-0038" title="">Analysis 4.13</a>) or reported at day 7 (see <a href="#CD010927-tbl-0005">Table 4</a> for additional data). </p> <p>Three trials conducted biochemical monitoring for either renal or hepatic adverse events (<a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a>; <a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>; <a href="./references#CD010927-bbs2-0025" title="YavoW , FayeB , KueteT , DjohanV , OgaSA , KassiRR , et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin‐piperaquine compared to artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub‐Saharan Africa. Malaria Journal2011;10(198):1‐8. ">Yavo 2011 AF</a>). Monitoring was adequate in all three trials but incompletely reported in one trial. No clinically important toxicities were reported (see <a href="#CD010927-tbl-0009">Table 8</a>). </p> <div class="table" id="CD010927-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">DHA‐P versus AL6: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate to detect adverse events?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 3, 28, and 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...altered liver enzymes (ALT)... was similar between the two treatment groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFT and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The median levels of alanine aminotransferase and creatinine before treatment, as well as the proportion of patients with values above the normal range (both clinically and non‐clinically significant, the latter not shown), were similar between the four study arms, and this did not change during the follow‐ups at day 7 and 28". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0025" title="YavoW , FayeB , KueteT , DjohanV , OgaSA , KassiRR , et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin‐piperaquine compared to artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub‐Saharan Africa. Malaria Journal2011;10(198):1‐8. ">Yavo 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In DP group from the beginning of the treatment to day 4, there was a decrease of the mean of AST and a small increase of ALT mean, while in the AL group, AST and ALT means increased. However, these variations were not significantly different. The decrease of the mean of creatinin from the beginning of the treatment to day 4 was not significant in the DP group but was significant in the AL group. In the two groups, the bilirubin decrease was significant". </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Adequate given that no clinically important abnormalities were seen.<br/> <sup>2</sup> Incomplete as trial authors did not present data and only gave a text summary.<br/> <sup>3</sup> Complete as trial authors presented data for the two days tested. </p> </div> </div> </section> </section> <section id="CD010927-sec-0084"> <h4 class="title">Comparison 5. DHA‐P versus artesunate plus amodiaquine</h4> <p>We found four trials which assessed this comparison; two in Africa and two in Asia; conducted between 2004 and 2009. </p> <p>Allocation concealment was assessed as low risk of bias in two trials (<a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a>; <a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>) and unclear in the other two. In all four trials laboratory staff were blinded to treatment allocation. </p> <section id="CD010927-sec-0085"> <h5 class="title">Total failure</h5> <p>In Africa, PCR‐unadjusted treatment failure at day 28 was lower following treatment with DHA‐P in both trials (RR 0.49, 95% CI 0.41 to 0.59, two trials, 2800 participants, <a href="./references#CD010927-fig-0040" title="">Analysis 5.1</a>). After PCR‐adjustment to exclude new infections, the difference between treatments was no longer statistically significant, but treatment failure was below 5% following treatment with DHA‐P in both trials, and above 5% following AS+AQ in Rwanda (two trials, 2486 participants, <a href="./references#CD010927-fig-0041" title="">Analysis 5.2</a>). One trial followed participants up to day 63 (<a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a>), and found no differences in PCR‐unadjusted or PCR‐adjusted treatment failure at this time point (one trial, 2292 participants, <a href="./references#CD010927-fig-0044" title="">Analysis 5.5</a>; <a href="./references#CD010927-fig-0045" title="">Analysis 5.6</a>). </p> <p>In Asia, PCR‐unadjusted treatment failure at day 28 was lower following treatment with DHA‐P (RR 0.38 95% CI 0.18 to 0.77, two trials, 482 participants, <a href="./references#CD010927-fig-0040" title="">Analysis 5.1</a>), and remained lower after PCR‐adjustment although the number of events was very low (RR 0.08, 95% CI 0.01 to 0.40, two trials, 466 participants, <a href="./references#CD010927-fig-0041" title="">Analysis 5.2</a>). One trial followed participants up to day 42 (<a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a>), and one to day 63 (<a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a>), when the differences remained statistically significant in favour of DHA‐P (<a href="./references#CD010927-fig-0042" title="">Analysis 5.3</a> to <a href="./references#CD010927-fig-0045" title="">Analysis 5.6</a>). </p> </section> <section id="CD010927-sec-0086"> <h5 class="title">Gametocytes</h5> <p>Two trials reported no statistically significant differences in gametocyte carriage during follow‐up but did not report the data (see <a href="#CD010927-tbl-0010">Table 9</a>). </p> <div class="table" id="CD010927-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">DHA‐P versus AS+AQ: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+AQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gametocyte prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐treatment gametocyte carriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PCV at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5 ± 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.0 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PCV at day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.4 ± 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.0 ± 3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients with anaemia at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Although there was no significant difference in haemoglobin levels between treatment groups at the time of admission, the rates of anemia at days 7 and 28 were significantly higher in AS+AQ recipients". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients with anaemia at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean increase in haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The mean increase of haemoglobin was similar among the treatment groups".</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Hb ‐ Haemoglobin<br/> PCV ‐ Packed cell volume<br/> Neutropenia ‐ neutrophil count &lt; 1000/µL </p> </div> </div> </section> <section id="CD010927-sec-0087"> <h5 class="title">Anaemia</h5> <p>Two trials reported no difference between PCV and haemoglobin levels respectively between the treatment groups (<a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a>; <a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a>; see <a href="#CD010927-tbl-0010">Table 9</a>). <a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> found that the prevalence of anaemia at day 7 (P = 0.02) and 28 (P = 0.006) was higher with AS+AQ (authors' own figures); this may be attributed to the recurrence of parasitaemia with both <i>P. falciparum</i> and <i>P. vivax</i> being higher in the AS+AQ group. </p> </section> <section id="CD010927-sec-0088"> <h5 class="title">Adverse events</h5> <p>The frequency of serious adverse events was lower with DHA‐P, and despite few events, this reached statistical significance (RR 0.40 95% CI 0.19 to 0.87, two trials, 2805 participants, <a href="./references#CD010927-fig-0046" title="">Analysis 5.7</a>, see <a href="./appendices#CD010927-sec-0106">Appendix 2</a> for details of serious adverse events). <a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a> reported 15 serious adverse events in 1003 participants treated with AS+AQ versus 10/1468 with DHA‐P. The exact nature of these serious adverse events was unclear, but the authors reported no differences in serious adverse events classified as possibly, probably, or definitely related to the trial drug (4/1003 versus 4/1468). </p> <p><a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> and <a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> found no difference in the number of participants with early vomiting (two trials, 650 participants, <a href="./references#CD010927-fig-0047" title="">Analysis 5.8</a>). </p> <p>Pyrexia was the only adverse event that was statistically more common with DHA‐P (RR 1.18 95% CI 1.02 to 1.37, one trial, 2471 participants, <a href="./references#CD010927-fig-0048" title="">Analysis 5.9</a>). </p> <p>Two trials conducted biochemical monitoring for renal or hepatic adverse events (<a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a>; <a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a>). Monitoring was adequate in both trials but incompletely reported in one trial. No clinically important toxicities were reported (see <a href="#CD010927-tbl-0011">Table 10</a>). </p> <div class="table" id="CD010927-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">DHA‐P versus AS+AQ: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participnts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate?  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs at one site only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No hepatotoxicity was observed, although analyses were performed at one site only (data not shown)". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFT and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The median levels of alanine aminotransferase and creatinine before treatment, as well as the proportion of patients with values above the normal range (both clinically and non‐clinically significant, the latter not shown), were similar between the four study arms, and this did not change during the follow‐ups at day 7 and 28". </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Adequate given that no clinically important abnormalities were seen.<br/> <sup>2</sup> Incomplete as trial authors did not present data and only gave a text summary.<br/> <sup>3</sup> Complete as trial authors presented data for the two days tested. </p> </div> </div> </section> </section> <section id="CD010927-sec-0089"> <h4 class="title">Comparison 6. DHA‐P versus artesunate plus sulfadoxine‐pyrimethamine</h4> <p>One trial conducted in Oceania in 2007 assessed this comparison (<a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a>). The trial authors did not describe any attempt to conceal allocation. Laboratory staff were blinded to treatment allocation. </p> <section id="CD010927-sec-0090"> <h5 class="title">Total failure</h5> <p>At day 28 PCR‐adjusted treatment failure was &gt; 10% in both groups (<a href="./references#CD010927-fig-0051" title="">Analysis 6.2</a>). </p> <p>There were no statistically significant differences in treatment failure between the two arms (one trial, 223 participants, <a href="./references#CD010927-fig-0050" title="">Analysis 6.1</a> to <a href="./references#CD010927-fig-0053" title="">Analysis 6.4</a>) </p> </section> <section id="CD010927-sec-0091"> <h5 class="title">Gametocytes</h5> <p>No significant differences in gametocyte carriage during follow‐up were reported (figures not reported). </p> </section> <section id="CD010927-sec-0092"> <h5 class="title">Anaemia</h5> <p>Trial authors reported haemoglobin levels remained similar in both groups throughout follow‐up (figures not reported). </p> </section> <section id="CD010927-sec-0093"> <h5 class="title">Adverse events</h5> <p>Monitoring for adverse events was undertaken but no differences between the groups were reported. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010927-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010927-sec-0094"></div> <p>For summaries of the main results for efficacy see; <a href="./full#CD010927-tbl-0001">summary of findings Table for the main comparison</a>; <a href="#CD010927-tbl-0012">Table 11</a>; <a href="#CD010927-tbl-0013">Table 12</a>; <a href="#CD010927-tbl-0014">Table 13</a>; <a href="#CD010927-tbl-0015">Table 14</a>; <a href="#CD010927-tbl-0016">Table 15</a>), and for adverse effects see <a href="./appendices#CD010927-sec-0107">Appendix 3</a>. </p> <div class="table" id="CD010927-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Asia and Oceania</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artemether‐lumefantrine for uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Asia and Oceania<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artemether‐lumefantrine (AL6) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AL6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/> (0.64 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1143<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (4 to 10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.01</b> <br/> (0.81 to 5.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>925<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> <br/> (0.47 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>323<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (4 to 17) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/> (0.14 to 7.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>298<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low or unclear risk of bias. Exclusion of trials as high risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: Statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Indonesia, Thailand, Papua New Guinea, and Myanmar.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: The 95% CI is wide and includes appreciable differences between drugs.<br/> <sup>5</sup> No serious risk of bias: This single trial is generally at low risk of bias.<br/> <sup>6</sup> Downgraded by 1 for serious indirectness: This single trial is from Myanmar. The results may not be easily generalized to elsewhere.<br/> <sup>7</sup> Two trials from Indonesia and Papua New Guinea reported outcomes at Day 42. At this timepoint there was no difference in PCR unadjusted or PCR adjusted treatment failure (two trials, 572 participants, <i>low quality evidence</i>). </p> </div> </div> <div class="table" id="CD010927-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for treating uncomplicated P. falciparum malaria in Asia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for treating uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Endemic settings in Asia<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus mefloquine (AS+MQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AS+MQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.02</b> <br/> (0.28 to 3.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3487<br/> (8 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (1 to 8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.41</b> <br/> (0.21 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3467<br/> (8 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.84</b> <br/> (0.69 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2715<br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (8 to 13) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.5</b> <br/> (0.3 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2500<br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,7,8,9</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (1 to 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of selection bias and detection bias. Exclusion of trials as high or unclear risk of bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: Six trials found very few recurrent parasitaemia in both groups. Two trials primarily conducted in Thailand in areas with multi‐drug resistance found an increased risk of recurrent parasitaemia with AS+MQ.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Vietnam, Thailand, Cambodia, Myanmar, India, and Laos.<br/> <sup>4</sup> No serious imprecision: The overall result is of no significant difference between treatments. However, where there is <i>P. falciparum</i> resistance to mefloquine, DHA‐P may be superior.<br/> <sup>5</sup> No serious imprecision: The overall result is of a statistically significant benefit with DHA‐P although this benefit may only be present where there is resistance to mefloquine.<br/> <sup>6</sup> Downgraded by one for serious inconsistency: Of the five trials, one from Thailand in 2005 found a statistically significant benefit with DHA‐P, one from Myanmar in 2009 found a benefit with DHA‐P, and three found no difference.<br/> <sup>7</sup> No serious indirectness: The trials were conducted in adults and children in Thailand, Cambodia, Myanmar, India, and Laos.<br/> <sup>8</sup> No serious imprecision: The overall result is of no significant difference between treatments. Although some trials found statistically significant differences, these may not be clinically important.<br/> <sup>9</sup> No serious inconsistency: There is a small amount of variability between trials, with only one trial showing a statistically significant benefit with DHA‐P. </p> </div> </div> <div class="table" id="CD010927-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for uncomplicated P. falciparum malaria in South America</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for uncomplicated <i>P. falciparum</i> malaria in South America</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Endemic settings in South America<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus mefloquine (AS+MQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AS+MQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Data unavailable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Data unavailable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 6.19</b> <br/> (1.4 to 27.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>445<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (1 to 24) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 9.55</b> <br/> (0.52 to 176.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>435<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: This trial is at low risk of selection bias and unclear risk of detection bias.<br/> <sup>2</sup> Downgraded by 1 for serious indirectness: This findings of this single trial are not easily generalized to other South American countries.<br/> <sup>3</sup> Downgraded by 1 for serious imprecision: Although this result reached statistical significance the number of events is very low, and there is a high possibility that this is a chance finding.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: There were too few events in this single trial to confidently exclude important effects. </p> </div> </div> <div class="table" id="CD010927-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum malaria in Africa</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for uncomplicated <i>P. falciparum</i> malaria in Africa</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Africa<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus amodiaquine (AS+AQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AS+AQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.49</b> <br/> (0.41 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2800<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (8 to 12) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.67</b> <br/> (0.42 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2486<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (2 to 4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.96</b> <br/> (0.86 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2292<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35 per 100</b> <br/> (32 to 39) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.8</b> <br/> (0.85 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1506<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in children in different transmission settings in Burkina Faso, Gabon, Nigeria, Rwanda, Uganda, Zambia, and Mozambique.<br/> <sup>4</sup> No serious imprecision: Both limits of the 95% CI imply appreciable benefit.<br/> <sup>5</sup> Downgraded by 1 for serious imprecision: The findings did not reach statistical significance.<br/> <sup>6</sup> No serious risk of bias: This finding is only reported in one trial which was at low risk of bias.<br/> <sup>7</sup> Downgraded by 1 for serious imprecision: There 95% CI are wide and include what might be important differences.<br/> <sup>8</sup> No data were presented for day 42. </p> </div> </div> <div class="table" id="CD010927-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falciparum malaria in Asia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Asia<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus amodiaquine (AS+AQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AS+AQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.38</b> <br/> (0.18 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>482<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (2 to 8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.08</b> <br/> (0.01 to 0.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>466<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.49</b> <br/> (0.27 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>304<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (5 to 17) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.14</b> <br/> (0.03 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>278<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Indonesia and Myanmar.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: Although this result reached statistical significance there are limited data, with few events. Larger trials are needed to have full confidence in this result.<br/> <sup>5</sup> No serious risk of bias: This finding is only reported in one trial which was generally at low risk of bias.<br/> <sup>6</sup> Downgraded by 1 for serious indirectness: This trial was from a single setting in Myanmar, and may not be easily generalized to elsewhere.<br/> <sup>7</sup> One trial from Indonesia conducted in 2007 presented day 42 outcomes and at this timepoint there was still an advantage on PCR‐unadjusted treatment failure with DHA‐P (RR 0.27, 95% CI 0.10 to 0.72, one trial, 152 participants, <i>moderate quality evidence</i> ), and PCR‐adjusted treatment failure (RR 0.10, 95% CI 0.01 to 0.81, one trial, 141 participants, <i>moderate quality evidence</i>). </p> </div> </div> <section id="CD010927-sec-0095"> <h3 class="title" id="CD010927-sec-0095">Summary of main results</h3> <p><i>DHA‐P versus artemether lumefantrine</i> </p> <p>In Africa, during 28 days follow‐up, DHA‐P is superior to AL6 at preventing further parasitaemia (<i>high quality evidence</i> ), and although PCR‐adjusted treatment failure was below 5% for both ACTs it was consistently lower with DHA‐P (<i>high quality evidence</i> ). DHA‐P has a longer prophylactic effect on new infections which may last for up to 63 days (<i>high quality evidence</i>). </p> <p>In Asia and Oceania, no differences in treatment failure have been shown at day 28 (<i>moderate quality evidence</i> ), or day 63 (<i>low quality evidence</i>). </p> <p>DHA‐P and AL6 appear to have similar adverse effect profiles (<i>moderate quality evidence</i> ). DHA‐P was associated with borderline prolongation of QTc interval but no difference was seen in prolonged QTc (<i>low quality evidence</i>) and no cardiac arrhythmias were reported. </p> <p><i>DHA‐P versus artesunate plus mefloquine</i> </p> <p>In Asia, during 28 days follow‐up, DHA‐P is as effective as AS+MQ at preventing further parasitaemia (<i>high quality evidence</i> ). Once adjusted by PCR to exclude new infections, treatment failure at day 28 was below 5% for both ACTs in all eight trials, but lower with DHA‐P in two trials from sites with multi‐drug resistant <i>P. falciparum</i> (<i>high quality evidence</i> ). Both combinations contain partner drugs with very long half‐lives and no consistent difference in preventing new infections has been seen between drugs over 63 days follow‐up (<i>moderate quality evidence</i>). </p> <p>In the only trial from South America, there were fewer recurrent parasitaemias over 63 days with AS+MQ (<i>low quality evidence</i> ), but there was no difference between treatments once adjusted by PCR for new infections (<i>low quality evidence</i>). </p> <p>Compared to AS+MQ, DHA‐P is associated with reduced nausea, vomiting, dizziness, sleeplessness, and palpitations (<i>moderate quality evidence</i> ). The only notable adverse event associated with DHA‐P was an increased frequency of prolongation of the QTc interval (<i>low quality evidence</i>), however no cardiac arrhythmias were reported in these trials. </p> </section> <section id="CD010927-sec-0096"> <h3 class="title" id="CD010927-sec-0096">Overall completeness and applicability of evidence</h3> <p>DHA‐P is one of the most studied ACTs, and we included 27 trials in this review, which enrolled 16,382 adults and children with uncomplicated malaria. Notably, these trials excluded infants aged less than six months and pregnant women, and further safety data is required for these groups. </p> <p>The efficacy of DHA‐P against uncomplicated <i>P. falciparum</i> malaria in adults and children however is now well established, and although there is only limited data from South America, it is likely that the findings of this review can be applied worldwide. </p> <p>Despite the high efficacy against asexual parasitaemia, DHA‐P appears to have a reduced efficacy against gametocytes. Compared to DHA‐P, both AS+MQ and AL6 reduce the carriage of gametocytes during the first 14 days post‐treatment. This deficiency has been discussed in the literature, and it is likely due to a relative underdosing of the artemisinin derivative in the combination. The clinical significance of this effect remains unclear as gametocyte carriage is only an indirect measure of transmission potential. Furthermore, any increased risk of transmission in the early period after treatment may be offset by the later improved prophylactic effect of DHA‐P. </p> <p>DHA‐P has been available and in use for several years despite the lack of a WHO prequalified formulation manufactured according to Good Manufacturing Practices Standards (GMP), and concerns about the stability and shelf‐life of the dihydroartemisinin combination (<a href="./references#CD010927-bbs2-0052" title="JansenFH . The pharmaceutical death‐ride of dihydroartemisinin. Malaria Journal2010;9(212):1‐4. ">Jansen 2010</a>; <a href="./references#CD010927-bbs2-0064" title="SchmatzD . Dihydroartemisinin: more life‐boat than death‐ride. Malaria Journal2010;9(212):1‐2. ">Schmatz 2010</a>). However, the Eurartesim® formulation evaluated by <a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> and <a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> has now been registered and approved for use by the European Medicines Agency (EMA) (<a href="./references#CD010927-bbs2-0049" title="European Medicines Agency. Eurartesim: Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/001199/WC500118116.pdf2011:1‐129. ">European Medicines Agency 2011</a>). </p> <p>The potential for prolongation of the QTc interval is the most notable adverse effect. This was noted in the EMA's report where they advised that DHA‐P should not be used in people who have, or are at risk of, QTc interval prolongation or cardiac arrhythmias, and should not be taken with other drugs which prolong the QTc interval (<a href="./references#CD010927-bbs2-0049" title="European Medicines Agency. Eurartesim: Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/001199/WC500118116.pdf2011:1‐129. ">European Medicines Agency 2011</a>). No participants were reported to have experienced confirmed cardiac arrhythmias in these studies. </p> <p>Systematic reviews in infectious diseases also need to consider the possibility of changing drug effects over time as drug resistance patterns change and develop. In this review, we partially explored this possibility by presenting all forest plots with trials arranged in chronological order, but we found no evidence of a decline in efficacy over time. However, a systematic review may not be the most appropriate way to examine these effects, as RCTs tend to be conducted for new drugs with little research interest once they are well established. Selection of first and second line antimalarials should therefore take into account other knowledge on antimalarial resistance, such as that produced by the WorldWide Antimalaria Resistance Network (<a href="./references#CD010927-bbs2-0073" title="WorldWide Antimalarial Resistance Network (WWARN). WWARN. http://www.wwarn.org/about‐us/our‐work2013. ">WWARN 2013</a>). </p> </section> <section id="CD010927-sec-0097"> <h3 class="title" id="CD010927-sec-0097">Quality of the evidence</h3> <p>We assessed the quality of the evidence in this review using the GRADE approach and presented the evidence in six summary of findings tables for efficacy (<a href="./full#CD010927-tbl-0001">summary of findings Table for the main comparison</a>; <a href="#CD010927-tbl-0013">Table 12</a>; <a href="#CD010927-tbl-0014">Table 13</a>; <a href="#CD010927-tbl-0012">Table 11</a>; <a href="#CD010927-tbl-0015">Table 14</a>; <a href="#CD010927-tbl-0016">Table 15</a>), and in three summary of findings tables for adverse events (in <a href="./appendices#CD010927-sec-0107">Appendix 3</a>). </p> <p>The evidence that DHA‐P is at least as effective as AS+MQ in Asia was of high quality. There was some statistical heterogeneity, with two trials (predominantly from trial sites in Thailand) finding slightly higher levels of treatment failure with AS+MQ. This may be a consequence of resistance to mefloquine in the area and was not considered sufficient to downgrade the evidence. </p> <p>The evidence for superiority of DHA‐P over AL6 in Africa was of high quality, with no reason to downgrade for risk of bias, inconsistency, indirectness, or imprecision. It should be noted that both DHA‐P and AL6 performed better than the WHO standard of 5% PCR‐adjusted treatment failure at day 28 in all trials. The choice between DHA‐P and AL6 may therefore be based more on considerations of adherence and cost, rather than efficacy. </p> <p>We also assessed the quality of evidence on comparative adverse effects and presented these in <a href="./appendices#CD010927-sec-0107">Appendix 3</a>. In general, the evidence was of moderate to low quality, meaning we can have reasonable confidence in some of these effects. </p> </section> <section id="CD010927-sec-0098"> <h3 class="title" id="CD010927-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>We found three recent systematic reviews of DHA‐P (<a href="./references#CD010927-bbs2-0054" title="KeatingGM . Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs2012;72(7):937‐61. ">Keating 2012</a>; <a href="./references#CD010927-bbs2-0059" title="NaingC , MakJW , AungK , WongJY . Efficacy and safety of dihydroartemisinin‐piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta‐analysis of randomised controlled studies. Transactions of the Royal Society of Tropical Medicine and Hygiene2013;107(2):65‐73. ">Naing 2013</a> &amp; <a href="./references#CD010927-bbs2-0074" title="WWARN DP Study Group. The effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin‐Piperaquine: A pooled analysis of Individual Patient Data. PLoS Medicine2013;10(12):e1001564. ">WWARN 2013b</a>), and reviewed the public assessment report of Eurartesim® by the EMA (<a href="./references#CD010927-bbs2-0049" title="European Medicines Agency. Eurartesim: Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/001199/WC500118116.pdf2011:1‐129. ">European Medicines Agency 2011</a>). </p> <p>The most recent systematic review (<a href="./references#CD010927-bbs2-0059" title="NaingC , MakJW , AungK , WongJY . Efficacy and safety of dihydroartemisinin‐piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta‐analysis of randomised controlled studies. Transactions of the Royal Society of Tropical Medicine and Hygiene2013;107(2):65‐73. ">Naing 2013</a>) includes 26 of the 27 trials we included in this review and reaches very similar conclusions: "DHA‐P is non‐inferior to other currently used ACTs such as AS+MQ and AL6" and "the better safety profile of DHA‐P and once‐daily dosage improves adherence. For these reasons, DHA‐P has the potential to become a first‐line antimalarial drug". </p> <p>The second review (<a href="./references#CD010927-bbs2-0054" title="KeatingGM . Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs2012;72(7):937‐61. ">Keating 2012</a>) is more narrative and focuses on the Eurartesim® formulation registered with the EMA. The review contains an extensive discussion of the effects of the formulation on the QTc interval, and the author concludes that "there are currently no data signalling that DHA‐P is associated with clinically significant arrhythmias". Similarly, the EMA public report concludes that "Treatment emergent QTc prolongation was asymptomatic in all cases", and "The magnitude of QTc prolongation is reduced if dosing occurs between meals". Conditional for registration, the pharmaceutical company agreed to undertake further post‐marketing evaluation of the effects of DHA‐P on the QTc interval and the potential for arrhythmias (<a href="./references#CD010927-bbs2-0049" title="European Medicines Agency. Eurartesim: Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/001199/WC500118116.pdf2011:1‐129. ">European Medicines Agency 2011</a>). </p> <p>The third review (<a href="./references#CD010927-bbs2-0074" title="WWARN DP Study Group. The effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin‐Piperaquine: A pooled analysis of Individual Patient Data. PLoS Medicine2013;10(12):e1001564. ">WWARN 2013b</a>) was based on individual patient data from 24 published and two unpublished studies. The analysis paid particular attention to the relationship between age, the drug dose administered, and treatment efficacy. The authors report that treatment failure following DHA‐P was highest in young children (aged between one and five years), and conclude that this is related to significant underdosing of both dihydroartemisinin and piperaquine in this age group, and to different pharmacokinetics in young children. On this basis, some further dose optimization of this combination is underway. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010927-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD010927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 1 Total failure (P. falciparum) Day 28 PCR‐unadjusted." data-id="CD010927-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 2 Total failure (P. falciparum) Day 28 PCR‐adjusted." data-id="CD010927-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 3 Total failure (P. falciparum) Day 42 PCR‐unadjusted." data-id="CD010927-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 4 Total failure (P. falciparum) Day 42 PCR‐adjusted." data-id="CD010927-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 5 Total failure (P. falciparum) Day 63 PCR‐unadjusted." data-id="CD010927-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 6 Total failure (P. falciparum) Day 63 PCR‐adjusted." data-id="CD010927-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 7 Gametocyte carriage." data-id="CD010927-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 7 Gametocyte carriage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 8 Gametocyte development (in those negative at baseline)." data-id="CD010927-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 8 Gametocyte development (in those negative at baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 9 Serious adverse events (including deaths)." data-id="CD010927-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 9 Serious adverse events (including deaths). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 10 Other adverse events: Gastrointestinal." data-id="CD010927-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 10 Other adverse events: Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 11 Other adverse events: Neuro‐psychiatric." data-id="CD010927-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 11 Other adverse events: Neuro‐psychiatric. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 12 Other adverse events: Cardio‐respiratory." data-id="CD010927-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 12 Other adverse events: Cardio‐respiratory. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 13 Other adverse events: Musculoskeletal/dermatological." data-id="CD010927-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 13 Other adverse events: Musculoskeletal/dermatological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 14 Sensitivity analysis: Total failure Day 63 PCR‐unadjusted." data-id="CD010927-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 14 Sensitivity analysis: Total failure Day 63 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 15 Sensitivity analysis: Total failure Day 63 PCR‐adjusted." data-id="CD010927-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine, Outcome 15 Sensitivity analysis: Total failure Day 63 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen, Outcome 1 Total failure PCR‐unadjusted." data-id="CD010927-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen, Outcome 1 Total failure PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen, Outcome 2 Total failure PCR‐adjusted." data-id="CD010927-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen, Outcome 2 Total failure PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 1 Total failure Day 28 PCR‐unadjusted." data-id="CD010927-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 1 Total failure Day 28 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 2 Total failure Day 28 PCR‐adjusted." data-id="CD010927-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 2 Total failure Day 28 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 3 Total failure Day 42 PCR‐unadjusted." data-id="CD010927-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 3 Total failure Day 42 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 4 Total failure Day 42 PCR‐adjusted." data-id="CD010927-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 4 Total failure Day 42 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 5 Total failure Day 63 PCR‐unadjusted." data-id="CD010927-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 5 Total failure Day 63 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 6 Total failure Day 63 PCR‐adjusted." data-id="CD010927-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 6 Total failure Day 63 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 1 Total failure (P. falciparum) Day 28 PCR‐unadjusted." data-id="CD010927-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 2 Total failure (P. falciparum) Day 28 PCR‐adjusted." data-id="CD010927-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 3 Total failure (P. falciparum) Day 42 PCR‐unadjusted." data-id="CD010927-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 4 Total failure (P. falciparum) Day 42 PCR‐adjusted." data-id="CD010927-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 5 Total failure (P. falciparum) Day 63 PCR‐unadjusted." data-id="CD010927-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 6 Total failure (P. falciparum) Day 63 PCR‐adjusted." data-id="CD010927-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 7 Gametocyte development (in those negative at baseline)." data-id="CD010927-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 7 Gametocyte development (in those negative at baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 8 Gametocyte carriage." data-id="CD010927-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 8 Gametocyte carriage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 9 Anaemia." data-id="CD010927-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 9 Anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 10 Serious adverse events (including deaths)." data-id="CD010927-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 10 Serious adverse events (including deaths). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 11 Other adverse events: Gastrointestinal." data-id="CD010927-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 11 Other adverse events: Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 12 Other adverse events: Neuro‐psychiatric." data-id="CD010927-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 12 Other adverse events: Neuro‐psychiatric. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 13 Other adverse events: Cardio‐respiratory." data-id="CD010927-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 13 Other adverse events: Cardio‐respiratory. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 14 Other adverse events: Musculoskeletal/dermatological." data-id="CD010927-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine, Outcome 14 Other adverse events: Musculoskeletal/dermatological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 1 Total failure (P. falciparum) Day 28 PCR‐unadjusted." data-id="CD010927-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 2 Total failure (P. falciparum) Day 28 PCR‐adjusted." data-id="CD010927-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 3 Total failure (P. falciparum) Day 42 PCR‐unadjusted." data-id="CD010927-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 4 Total failure (P. falciparum) Day 42 PCR‐adjusted." data-id="CD010927-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 5 Total failure (P. falciparum) Day 63 PCR‐unadjusted." data-id="CD010927-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 6 Total failure (P. falciparum) Day 63 PCR‐adjusted." data-id="CD010927-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 7 Serious adverse events (including deaths)." data-id="CD010927-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 7 Serious adverse events (including deaths). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 8 Other adverse events: Gastrointestinal." data-id="CD010927-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 8 Other adverse events: Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 9 Other adverse events: Neuro‐psychiatric." data-id="CD010927-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 9 Other adverse events: Neuro‐psychiatric. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 10 Other adverse events: Cardio‐respiratory." data-id="CD010927-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine, Outcome 10 Other adverse events: Cardio‐respiratory. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total failure (P. falciparum) Day 28 PCR‐unadjusted." data-id="CD010927-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total failure (P. falciparum) Day 28 PCR‐adjusted." data-id="CD010927-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total failure (P. falciparum) Day 42 PCR‐unadjusted." data-id="CD010927-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010927-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/urn:x-wiley:14651858:media:CD010927:CD010927-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_t/tCD010927-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total failure (P. falciparum) Day 42 PCR‐adjusted." data-id="CD010927-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010927/media/CDSR/CD010927/image_n/nCD010927-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010927-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Africa</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated <i>P. falciparum</i> malaria in Africa</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Malaria endemic settings in Africa<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artemether‐lumefantrine (AL6) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> AL6</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.34</b> <br/> (0.30 to 0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6200<br/> (9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (7 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.42</b> <br/> (0.29 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5417<br/> (9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.71</b> <br/> (0.65 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3200<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,3,4,6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (29 to 35) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.72</b> <br/> (0.50 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2097<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,3,7,8,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (3 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.,<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of studies at high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in different transmission settings in East, West and Southern Africa. Most studies were limited to children.<br/> <sup>4</sup> No serious imprecision: Both limits of the 95% CI imply appreciable benefit, and the overall meta‐analysis is adequately powered to detect this result.<br/> <sup>5</sup> No serious imprecision: Although there is a benefit in favour of DHA‐P, PCR‐adjusted treatment failure was below 5% with both drugs.<br/> <sup>6</sup> No serious inconsistency: At this timepoint there is more inconsistency between trials. Both show a benefit with DHA‐P but there is variation in the size of this benefit.<br/> <sup>7</sup> Seven studies from East, West and Southern Africa reported outcomes at day 42. At this timepoint DHA‐P still had an advantage over AL6 on PCR‐unadjusted treatment failure (RR 0.60, 95% CI 0.53 to 0.67, seven studies, 3301, <i>high quality evidence</i> ), and PCR‐adjusted treatment failure (RR 0.58, 95% CI 0.41 to 0.81, seven studies, 2559 participants, <i>moderate quality evidence</i>).<br/> <sup>8</sup> No serious inconsistency: Statistical heterogeneity was low.<br/> <sup>9</sup> No serious imprecision: Both ACTs performed well in these two trials with low levels of treatment failure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Africa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Search set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CIDG SR<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> CENTRAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> MEDLINE<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> EMBASE<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> LILACS<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>malaria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>arte*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydroarte*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>amodiaq$</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lumefantrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coartem$</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mefloquine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 or 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 or 5 or 6 or 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 and 8 and 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 10 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 10 to human</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> —</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Cochrane Infectious Diseases Group Specialized Register.<br/> <sup>b</sup>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<a href="./references#CD010927-bbs2-0055" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Lefebvre 2008</a>); upper case: MeSH or EMTREE heading; lower case: free text term. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measure (Total failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR<sup>b</sup>‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Numerator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Numerator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Denominator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Primary analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusions after enrolment<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing or indeterminate PCR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 1<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Primary analysis' except: missing or indeterminate PCR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 2<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 1' except: new infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 3<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 2' except: exclusions after enrolment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis 4<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As 'Sensitivity analysis 2' except: exclusions after enrolment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included as successes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Note: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations.<br/> <sup>b</sup>PCR: polymerase chain reaction.<br/> <sup>c</sup>'Excluded' means removed from the calculation.<br/> <sup>d</sup>To re‐classify all indeterminate or missing PCR results as treatment failures in the PCR‐adjusted analysis.<br/> <sup>e</sup>To re‐classify all PCR‐confirmed new infections as treatment successes in the PCR‐adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have proceeded to develop a recrudescence after the new infection.)<br/> <sup>f</sup>To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR‐unadjusted total failure, this represents a true worse‐case scenario.<br/> <sup>g</sup>To re‐classify all exclusions after enrolment (losses to follow‐up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measure (Total failure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">DHA‐P versus AS+MQ: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion with gametocytes at any timepoint after treatment (on or after day 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean across all groups was 0.10 (95% CI 0.03 to 0.20). No difference between groups (published data). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte incidence at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte incidence at day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gametocyte carriage in DHA‐P group was higher than in AS+MQ group (published data). Figures not given. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for fixed‐dose AS+MQ combination.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2</p> <p>(130/6420)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> <p>(23/3108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Published data in paper presented as "person gametocytemia weeks per 100 person weeks".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median decrease in HCT by day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean decrease in HCT up to day 7 then recovery in all groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute changes in HCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean decrease in HCT up to day 7 then recovery in all groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0010" title="JanssensB , vanHerpM , GoubertL , ChanS , UongS , NongS , et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health2007;12(2):251‐9. ">Janssens 2007 KHM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean HCT at day 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 % (3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.2% (3.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Patients in both treatment groups showed similar haematological<br/> recovery during the 63‐day follow‐up period". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean HCT days 7 to 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"the mean hematocrit after treatment did not significantly differ between groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean haemoglobin at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for supervised treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion anaemic (Hb &lt; 10 g/dL) on day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data presented are for supervised treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean increase in haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The mean increase of haemoglobin was similar among the treatment groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean increase in Hb from day 0 to day 63 in g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 ± 2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 ± 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Hb ‐ Haemoglobin<br/> HCT ‐ Haematocrit </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">DHA‐P versus AS+MQ: Additional secondary outcomes data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">DHA‐P versus AS+MQ/AL6: QTc measurements</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correction<br/> method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431 to 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.066</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431 to 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.043</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prolonged QTc (&gt; 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc increase &gt; 60 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AL6<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>1553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Borderline QTc (431‐450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Borderline QTc (431‐450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prolonged QTc (&gt; 450ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc &gt; 500 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>QTc increase &gt; 60 ms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTcF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> In this analysis the direction of effect is reversed. These figures have been confirmed as correct by the study authors.<br/> <sup>2</sup> Figures not presented in paper: Taken from <a href="./references#CD010927-fig-0038" title="">Analysis 4.13</a>.<br/> N/R ‐ Not reported<br/> QTcB ‐ QT interval corrected for rate and gender using Bazett's method.<br/> QTcF ‐ Qt interval corrected for rate and gender using Fridericia's method. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">DHA‐P versus AS+MQ/AL6: QTc measurements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">DHA‐P versus AS+MQ: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate to detect adverse events?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U&amp;E, LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No biochemical evidence of toxicity was observed".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>U&amp;E, LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No patient had abnormal liver and renal function test results of clinical significance, both at entry and at day 7". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0023" title="TranTH , DolecekC , PhamPM , NguyenTD , NguyenTT , LeHT , et al. Dihydroartemisinin‐piperaquine against multidrug‐resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. The Lancet2004; Vol. 363, issue 9402:18‐22. ">Tran 2004 VNM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 3,7,28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no significant differences between the three groups in the results of liver function tests done on all patients on days 3, 7, and 28". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0, 28, 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Other than elevated liver parameters, as might be expected in this population, there were no relevant changes in biochemistry parameters".' </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Judged as adequate given that no clinically important abnormalities were seen at day 7. Longer follow‐up is therefore probably unnecessary.<br/> <sup>2</sup> Judged as incomplete as data were not presented. Only a text summary was given.<br/> <sup>3</sup> Judged as inadequate as biochemical abnormalities are likely to occur earlier than day 28. </p> <p>LFT = Liver Function Tests</p> <p>U&amp;E = Urea and electrolytes</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">DHA‐P versus AS+MQ: Biochemical monitoring and adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">DHA‐P versus AS+MQ dosing regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year of study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age limits</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+MQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0004" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004a THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 14 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0005" title="AshleyEA , KrudsoodS , PhaiphunL , SrivilairitS , McGreadyR , LeowattanaW , et al. Randomized, controlled dose‐optimization studies of dihydroartemisinin‐piperaquine for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand. Journal of Infectious Diseases2004;190(10):1773‐82. ">Ashley 2004b THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 65 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0006" title="AshleyEA , McGreadyR , HutagalungR , PhaiphunL , SlightT , ProuxS , et al. A randomized, controlled study of a simple, once‐daily regimen of dihydroartemisinin‐piperaquine for the treatment of uncomplicated, multidrug‐resistant falciparum malaria. Clinical Infectious Diseases2005; Vol. 41, issue 4:425‐32. ">Ashley 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 65 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs or 3 divided doses at 0, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0008" title="GrandeT , BernasconiA , ErhartA , GamboaD , CasapiaM , DelgadoC , et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One2007;2(10):e1101. ">Grande 2007 PER</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 to 60 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total dose: 6.3 mg/kg DHA and 50.4 mg/kg PQP in 3 divided doses, given once daily for 3 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0010" title="JanssensB , vanHerpM , GoubertL , ChanS , UongS , NongS , et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin‐piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health2007;12(2):251‐9. ">Janssens 2007 KHM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adult total dose</b>: 6 mg/kg DHA and + 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs </p> <p><b>Children total dose</b>: 6.4 mg/kg DHA + 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults</b>: 100 mg AS plus 500 mg MQ twice daily on day 0, 200 mg AS once daily on days 1 and 2. </p> <p><b>Children</b>: 4 mg/kg AS once daily for 3 days + 25 mg/kg MQ in 2 equal doses on day 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0015" title="MayxayM , ThongpraseuthV , KhanthavongM , LindegårdhN , BarendsM , KeolaS , et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin‐piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health2006;11(8):1157‐65. ">Mayxay 2006 LAO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 mg/kg DHA + 50.4 mg/kg P in 3 divided doses, once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 15 mg MQ base/kg on day 1 and 10 mg base/kg on day 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0019" title="SmithuisF , KyawMK , PheO , AyeKZ , HtetL , BarendsM , et al. Efficacy and effectiveness of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in falciparum malaria: an open‐label randomised comparison. The Lancet2006;367(9528):2075‐85. ">Smithuis 2006 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 mg/kg DHA + 50.4 mg/kg P in 3 divided doses, once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days.</p> <p>25 mg MQ base/kg as a single dose on day 0.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/kg DHA + 20 mg/kg P daily, given once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fixed combination</b>: 4 mg/kg AS + 8.8 mg/kg MQ daily, once daily for 3 days. </p> <p><b>Loose combination</b>: 4 mg/kg AS once daily for 3 days + 25 mg base/kg MQ as a single dose on day 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0021" title="TangpukdeeN , KrudsoodS , ThanachartwetW , ChalermrutK , PengruksaC , SrivilairitS , et al. An open randomized clinical trial of Artekin vs artesunate‐mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health2005;36(5):1085‐91. ">Tangpukdee 2005 THA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 14 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg/kg DHA + 45 mg/kg P in 3 divided doses, given once daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 8 mg/kg MQ once daily for 3 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0023" title="TranTH , DolecekC , PhamPM , NguyenTD , NguyenTT , LeHT , et al. Dihydroartemisinin‐piperaquine against multidrug‐resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. The Lancet2004; Vol. 363, issue 9402:18‐22. ">Tran 2004 VNM</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg/320 mg tablets<br/> <b>Adults</b>: 2 tablets at 0, 6, 24, and 48 hrs </p> <p><b>Children &lt; 15 yrs</b>: 1 tablet at 0, 6, 24, and 48 hrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg AS once daily for 3 days + 25 mg base/kg MQ as 2 divided doses 6 hrs apart on day 3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0024" title="GarganoN , UbbenD , TommasiniS , BacchieriA , CorsiM , BhattacharyyaPC , et al. Therapeutic efficacy and safety of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malaria Journal2012;11(233):1‐12. MayxayM , KeomanyS , KhanthavongM , SouvannasingP , StepniewskaK , KhomthilathT , et al. A phase III, randomized, non‐inferiority trial to assess the efficacy and safety of dihydroartemisinin‐piperaquine in comparison with artesunate‐mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. American Journal of Tropical Medicine and Hygiene2010;83(6):1221‐9. ValechaN , PhyoA P , MayxayM , NewtonP N , KrudsoodS , KeomanyS , et al. An open‐label, randomised study of dihydroartemisinin‐piperaquine versus artesunate‐mefloquine for falciparum malaria in Asia. PLoS One2010;5(7):e11880. ">Valecha 2010 AS</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3m to 65 yrs (≥18 yrs in India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA: 2.25 mg/kg DHA + 18 mg/kg P daily dose for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4mg/kg AS once daily for 3 days + MQ none on day 0, then 15 mg/kg once on day 1 and 10 mg/kg once on day 2 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">DHA‐P versus AS+MQ dosing regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">DHA‐P versus AL6: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AL6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0017" title="RatcliffA , SiswantoroH , KenangalemE , MaristelaR , WuwungRM , LaihadF , et al. Two fixed‐dose artemisinin combinations for drug‐resistant falciparum and vivax malaria in Papua, Indonesia: an open‐label randomised comparison. The Lancet2007;369(9563):757‐65. ">Ratcliff 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Person gametocytemia weeks per 1000 person weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0013" title="DavisWA , ClarkePM , SibaPM , KarunajeewaHA , DavyC , MuellerI , et al. Cost‐effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization2011;89(3):211‐20. KarunajeewaHA , MuellerI , SennM , LinE , LawI , GomorraiPS , et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine2008;359(24):2545‐57. ">Karunajeewa 2008 PNG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐treatment gametocytemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0026" title="YekaA , DorseyG , KamyaMR , TalisunaA , LugemwaM , RwakimariJB , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One2008;3(6):e2390. ">Yeka 2008 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean increase in Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0016" title="MensPF , SawaP , vanAmsterdamSM , VersteegI , OmarSA , SchalligHD , et al. A randomized trial to monitor the efficacy and effectiveness by QT‐NASBA of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malaria Journal2008;7(237):1‐8. ">Mens 2008 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Final mean Hb level (mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.15 ± 1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.79 ± 1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0003" title="ArinaitweE , SandisonTG , WanziraH , KakuruA , HomsyJ , KalamyaJ , et al. Artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clinical Infectious Diseases2009;49(11):1629‐37. CreekD , BigiraV , ArinaitweE , WanziraH , KakuruA , TapperoJ , et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin‐piperaquine compared with artemether‐lumefantrine for uncomplicated malaria. American Journal of Tropical Medicine and Hygiene2010;83(4):873‐5. KakuruA , JagannathanP , ArinaitweE , WanziraH , MuhindoM , BigiraV , et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. American Journal of Tropical Medicine and Hygiene2013;88(4):736‐43. KatrakS , GasasiraA , ArinaitweE , KakuruA , WanziraH , BigiraV , et al. Safety and tolerability of artemether‐lumefantrine versus dihydroartemisinin‐piperaquine for malaria in young HIV‐infected and uninfected children. Malaria Journal2009;8(272):1‐8. ">Arinaitwe 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean Hb recovery (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 ± 1.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 ± 1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0002" title="AgarwalA , McMorrowM , OnyangoP , OtienoK , OderoC , WilliamsonJ , et al. A randomized trial of artemether‐lumefantrine and dihydroartemisinin‐piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malaria Journal2013;12(254):1‐8. ">Agarwal 2013 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Hb increase from baseline in patients not re‐infected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P value for difference in mean Hb increase in re‐infected patients and those not re‐infected is given as 0.9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Hb increase from baseline in re‐infected patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Hb ‐ Haemoglobin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">DHA‐P versus AL6: Additional secondary outcomes data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">DHA‐P versus AL6: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate to detect adverse events?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0007" title="BassatQ , MulengaM , TintoH , PiolaP , BorrmannS , MenéndezC , et al. Dihydroartemisinin‐piperaquine and artemether‐lumefantrine for treating uncomplicated malaria in African children: a randomised, non‐inferiority trial. PLoS One2009;4(11):e7871. BorrmannS , SasiP , MwaiL , BashraheilM , AbdallahA , MuriithiS , et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin‐based combination treatments on the Kenyan coast. PloS One2011;6(11):e26005. NamboziM , VanGeertruydenJP , HachizovuS , ChapondaM , MukwamatabaD , MulengaM , et al. Safety and efficacy of dihydroartemisininpiperaquine versus artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malaria Journal2011;10(50):1‐9. ">Bassat 2009 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 3, 28, and 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"...altered liver enzymes (ALT)... was similar between the two treatment groups".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFT and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The median levels of alanine aminotransferase and creatinine before treatment, as well as the proportion of patients with values above the normal range (both clinically and non‐clinically significant, the latter not shown), were similar between the four study arms, and this did not change during the follow‐ups at day 7 and 28". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0025" title="YavoW , FayeB , KueteT , DjohanV , OgaSA , KassiRR , et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin‐piperaquine compared to artemether‐lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub‐Saharan Africa. Malaria Journal2011;10(198):1‐8. ">Yavo 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In DP group from the beginning of the treatment to day 4, there was a decrease of the mean of AST and a small increase of ALT mean, while in the AL group, AST and ALT means increased. However, these variations were not significantly different. The decrease of the mean of creatinin from the beginning of the treatment to day 4 was not significant in the DP group but was significant in the AL group. In the two groups, the bilirubin decrease was significant". </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Adequate given that no clinically important abnormalities were seen.<br/> <sup>2</sup> Incomplete as trial authors did not present data and only gave a text summary.<br/> <sup>3</sup> Complete as trial authors presented data for the two days tested. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">DHA‐P versus AL6: Biochemical monitoring and adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">DHA‐P versus AS+AQ: Additional secondary outcomes data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DHA‐P</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AS+AQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Gametocyte carriage</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gametocyte prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post‐treatment gametocyte carriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Figures not given.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Anaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PCV at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5 ± 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.0 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean PCV at day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.4 ± 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.0 ± 3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010927-bbs2-0009" title="HasugianAR , PurbaHL , KenangalemE , WuwungRM , EbsworthEP , MaristelaR , et al. Dihydroartemisinin‐piperaquine versus artesunate‐amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug‐resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases2007;44(8):1067‐74. ">Hasugian 2007 IDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients with anaemia at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Although there was no significant difference in haemoglobin levels between treatment groups at the time of admission, the rates of anemia at days 7 and 28 were significantly higher in AS+AQ recipients". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of patients with anaemia at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010927-bbs2-0020" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010 MMR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean increase in haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The mean increase of haemoglobin was similar among the treatment groups".</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Hb ‐ Haemoglobin<br/> PCV ‐ Packed cell volume<br/> Neutropenia ‐ neutrophil count &lt; 1000/µL </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">DHA‐P versus AS+AQ: Additional secondary outcomes data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">DHA‐P versus AS+AQ: Biochemical monitoring and adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participnts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days reported  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days tested adequate?  </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For adequate testing, was reporting complete? </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results as presented in the paper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0012" title="KaremaC , FanelloCI , vanOvermeirC , vanGeertruydenJP , vanDorenW , NgamijeD , et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene2006; Vol. 100, issue 12:1105‐11. ">Karema 2006 RWA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFTs at one site only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 0 and 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No hepatotoxicity was observed, although analyses were performed at one site only (data not shown)". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010927-bbs2-0022" title="The Four Artemisinin‐Based Combinations (4ABC) Study Group. A head‐to‐head comparison of four artemisinin‐based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine2011;8(11):e1001119. ">The 4ABC Study 2011 AF</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LFT and renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days 7 and 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The median levels of alanine aminotransferase and creatinine before treatment, as well as the proportion of patients with values above the normal range (both clinically and non‐clinically significant, the latter not shown), were similar between the four study arms, and this did not change during the follow‐ups at day 7 and 28". </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Adequate given that no clinically important abnormalities were seen.<br/> <sup>2</sup> Incomplete as trial authors did not present data and only gave a text summary.<br/> <sup>3</sup> Complete as trial authors presented data for the two days tested. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">DHA‐P versus AS+AQ: Biochemical monitoring and adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0012"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Asia and Oceania</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artemether‐lumefantrine for uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Asia and Oceania<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artemether‐lumefantrine (AL6) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AL6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/> (0.64 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1143<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (4 to 10) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.01</b> <br/> (0.81 to 5.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>925<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> <br/> (0.47 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>323<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (4 to 17) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/> (0.14 to 7.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>298<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low or unclear risk of bias. Exclusion of trials as high risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: Statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Indonesia, Thailand, Papua New Guinea, and Myanmar.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: The 95% CI is wide and includes appreciable differences between drugs.<br/> <sup>5</sup> No serious risk of bias: This single trial is generally at low risk of bias.<br/> <sup>6</sup> Downgraded by 1 for serious indirectness: This single trial is from Myanmar. The results may not be easily generalized to elsewhere.<br/> <sup>7</sup> Two trials from Indonesia and Papua New Guinea reported outcomes at Day 42. At this timepoint there was no difference in PCR unadjusted or PCR adjusted treatment failure (two trials, 572 participants, <i>low quality evidence</i>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artemether‐lumefantrine for uncomplicated P. falciparum malaria in Asia and Oceania</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0013"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for treating uncomplicated P. falciparum malaria in Asia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for treating uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Endemic settings in Asia<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus mefloquine (AS+MQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AS+MQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.02</b> <br/> (0.28 to 3.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3487<br/> (8 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (1 to 8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.41</b> <br/> (0.21 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3467<br/> (8 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.84</b> <br/> (0.69 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2715<br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (8 to 13) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.5</b> <br/> (0.3 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2500<br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,7,8,9</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (1 to 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of selection bias and detection bias. Exclusion of trials as high or unclear risk of bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: Six trials found very few recurrent parasitaemia in both groups. Two trials primarily conducted in Thailand in areas with multi‐drug resistance found an increased risk of recurrent parasitaemia with AS+MQ.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Vietnam, Thailand, Cambodia, Myanmar, India, and Laos.<br/> <sup>4</sup> No serious imprecision: The overall result is of no significant difference between treatments. However, where there is <i>P. falciparum</i> resistance to mefloquine, DHA‐P may be superior.<br/> <sup>5</sup> No serious imprecision: The overall result is of a statistically significant benefit with DHA‐P although this benefit may only be present where there is resistance to mefloquine.<br/> <sup>6</sup> Downgraded by one for serious inconsistency: Of the five trials, one from Thailand in 2005 found a statistically significant benefit with DHA‐P, one from Myanmar in 2009 found a benefit with DHA‐P, and three found no difference.<br/> <sup>7</sup> No serious indirectness: The trials were conducted in adults and children in Thailand, Cambodia, Myanmar, India, and Laos.<br/> <sup>8</sup> No serious imprecision: The overall result is of no significant difference between treatments. Although some trials found statistically significant differences, these may not be clinically important.<br/> <sup>9</sup> No serious inconsistency: There is a small amount of variability between trials, with only one trial showing a statistically significant benefit with DHA‐P. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for treating uncomplicated P. falciparum malaria in Asia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0014"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for uncomplicated P. falciparum malaria in South America</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for uncomplicated <i>P. falciparum</i> malaria in South America</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Endemic settings in South America<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus mefloquine (AS+MQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> AS+MQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Data unavailable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Data unavailable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 6.19</b> <br/> (1.4 to 27.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>445<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (1 to 24) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 9.55</b> <br/> (0.52 to 176.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>435<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: This trial is at low risk of selection bias and unclear risk of detection bias.<br/> <sup>2</sup> Downgraded by 1 for serious indirectness: This findings of this single trial are not easily generalized to other South American countries.<br/> <sup>3</sup> Downgraded by 1 for serious imprecision: Although this result reached statistical significance the number of events is very low, and there is a high possibility that this is a chance finding.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: There were too few events in this single trial to confidently exclude important effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus mefloquine for uncomplicated P. falciparum malaria in South America</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0015"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum malaria in Africa</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for uncomplicated <i>P. falciparum</i> malaria in Africa</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Africa<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus amodiaquine (AS+AQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AS+AQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.49</b> <br/> (0.41 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2800<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (8 to 12) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.67</b> <br/> (0.42 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2486<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,5</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (2 to 4) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.96</b> <br/> (0.86 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2292<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35 per 100</b> <br/> (32 to 39) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.8</b> <br/> (0.85 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1506<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,6,7,8</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in children in different transmission settings in Burkina Faso, Gabon, Nigeria, Rwanda, Uganda, Zambia, and Mozambique.<br/> <sup>4</sup> No serious imprecision: Both limits of the 95% CI imply appreciable benefit.<br/> <sup>5</sup> Downgraded by 1 for serious imprecision: The findings did not reach statistical significance.<br/> <sup>6</sup> No serious risk of bias: This finding is only reported in one trial which was at low risk of bias.<br/> <sup>7</sup> Downgraded by 1 for serious imprecision: There 95% CI are wide and include what might be important differences.<br/> <sup>8</sup> No data were presented for day 42. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum malaria in Africa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010927-tbl-0016"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falciparum malaria in Asia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated <i>P. falciparum</i> malaria in Asia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating uncomplicated <i>P. falciparum</i> malaria<br/> <b>Settings:</b> Asia<br/> <b>Intervention:</b> Dihydroartemisinin‐piperaquine (DHA‐P)<br/> <b>Comparison:</b> Artesunate plus amodiaquine (AS+AQ) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AS+AQ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DHA‐P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.38</b> <br/> (0.18 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>482<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> <br/> (2 to 8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.08</b> <br/> (0.01 to 0.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>466<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Treatment failure</b> </p> <p><b>Day 63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐unadjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.49</b> <br/> (0.27 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>304<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (5 to 17) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PCR‐adjusted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.14</b> <br/> (0.03 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>278<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6,7</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 6) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection bias did not change the result.<br/> <sup>2</sup> No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.<br/> <sup>3</sup> No serious indirectness: The trials were conducted in adults and children in Indonesia and Myanmar.<br/> <sup>4</sup> Downgraded by 1 for serious imprecision: Although this result reached statistical significance there are limited data, with few events. Larger trials are needed to have full confidence in this result.<br/> <sup>5</sup> No serious risk of bias: This finding is only reported in one trial which was generally at low risk of bias.<br/> <sup>6</sup> Downgraded by 1 for serious indirectness: This trial was from a single setting in Myanmar, and may not be easily generalized to elsewhere.<br/> <sup>7</sup> One trial from Indonesia conducted in 2007 presented day 42 outcomes and at this timepoint there was still an advantage on PCR‐unadjusted treatment failure with DHA‐P (RR 0.27, 95% CI 0.10 to 0.72, one trial, 152 participants, <i>moderate quality evidence</i> ), and PCR‐adjusted treatment failure (RR 0.10, 95% CI 0.01 to 0.81, one trial, 141 participants, <i>moderate quality evidence</i>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Dihydroartemisinin‐piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falciparum malaria in Asia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/full#CD010927-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.28, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.21, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.69, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 South America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.19 [1.40, 27.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.30, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 South America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.55 [0.52, 176.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gametocyte carriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Gametocyte carriage day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.66, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Gametocyte carriage day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.57, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Gametocyte carriage day 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.11 [3.26, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Gametocyte carriage day 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.44 [0.80, 110.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Gametocyte carriage day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.55 [1.80, 50.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Gametocyte development (in those negative at baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [1.13, 8.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events (including deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.59, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Other adverse events: Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Early vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.47, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.05, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Other adverse events: Neuro‐psychiatric <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.66, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Sleeplessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.40, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.24, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.13, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Other adverse events: Cardio‐respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.3 [0.08, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Prolonged QT interval (reported as adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.72, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Prolonged QT interval (Bazett's correction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.20, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Prolonged QT interval (Fridericia's correction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.52, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Other adverse events: Musculoskeletal/dermatological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.60, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.63, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Urticaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.26, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis: Total failure Day 63 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Total failure (P. falciparum) Day 63 PCR‐unadjusted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.52, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Total failure Day 63 PCR‐unadjusted (losses to follow‐up included as failures)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.65, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Total failure Day 63 PCR‐unadjusted (losses to follow‐up included as successes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.52, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Sensitivity analysis: Total failure Day 63 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Total failure (P. falciparum) Day 63 PCR‐adjusted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Total failure Day 63 PCR‐adjusted (indeterminate PCR included as failures)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Total failure Day 63 PCR‐adjusted (new infections included as successes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.34, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Total failure Day 63 PCR‐adjusted (losses to follow‐up included as failures)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Total failure Day 63 PCR‐adjusted (losses to follow‐up included as successes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.34, 1.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus mefloquine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.84, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Day 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.84, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 6.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Day 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 6.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dihydroartemisinin‐piperaquine dose analysis: 3 dose versus 4 dose regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure Day 28 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.25, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.10, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.19, 5.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure Day 28 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.15, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total failure Day 42 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.40, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total failure Day 42 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.20, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.14, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total failure Day 63 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.62, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.52, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total failure Day 63 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.28, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 DHA‐P 4 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 DHA‐P 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.26, 2.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.30, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Asia and Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.64, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.29, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Asia and Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.81, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.53, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Asia and Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.65, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.41, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Asia and Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.75, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.65, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.47, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.14, 7.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gametocyte development (in those negative at baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Gametocyte carriage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Gametocyte carriage day 1 to 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [1.48, 12.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Gametocyte carriage day 15 to 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.06, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Gametocyte carriage day 29 to 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Mean haemoglobin (g/dL) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.09, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Mean haemoglobin (g/dL) at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.03, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mean haemoglobin (g/dL) at day 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.02, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Mean change in haemoglobin (g/dL) from baseline to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Mean change in haemoglobin (g/dL) from baseline to day 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.00, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events (including deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.93, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Other adverse events: Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Early vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.00, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.89, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.36, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Other adverse events: Neuro‐psychiatric <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Sleeplessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.69, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.67, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 69.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Other adverse events: Cardio‐respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Coryza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Prolonged QTc interval (reported as adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.51, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Prolonged QTc interval (Bazett's correction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.91, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Prolonged QTc interval (Fridericia's correction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.09, 10.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Other adverse events: Musculoskeletal/dermatological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.03, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Face oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.12, 69.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artemether‐lumefantrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.41, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.18, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.42, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total failure (<i>P. falciparum</i>) Day 63 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total failure (<i>P. falciparum</i>) Day 63 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.85, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events (including deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.19, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other adverse events: Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Early vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.44, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.62, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.83, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.51, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Other adverse events: Neuro‐psychiatric <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.14, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Sleeplessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.44, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Other adverse events: Cardio‐respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus amodiaquine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010927-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total failure (<i>P. falciparum</i>) Day 28 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.62, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total failure (<i>P. falciparum</i>) Day 28 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total failure (<i>P. falciparum</i>) Day 42 PCR‐unadjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.74, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total failure (<i>P. falciparum</i>) Day 42 PCR‐adjusted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oceania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.39, 1.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Dihydroartemisinin‐piperaquine versus Artesunate plus sulfadoxine‐pyrimethamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010927/references#CD010927-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010927&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010927-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010927-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010927-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010927"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010927"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010927"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010927\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010927\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010927"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010927&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010927';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010927/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010927/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010927%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726785345"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010927/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726785349"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010927/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9c1ceab29368',t:'MTc0MDcyNjc4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 